Medical monitoring device for harmonizing physiological measurements

Information

  • Patent Grant
  • 11026604
  • Patent Number
    11,026,604
  • Date Filed
    Friday, July 13, 2018
    6 years ago
  • Date Issued
    Tuesday, June 8, 2021
    3 years ago
Abstract
Systems, methods, apparatuses, and medical devices for harmonizing data from a plurality of non-invasive sensors are described. A physiological parameter can be determined by harmonizing data between two or more different types of non-invasive physiological sensors interrogating the same or proximate measurement sites. Data from one or more first non-invasive sensors can be utilized to identify one or more variables that are useful in one or more calculations associated with data from one or more second non-invasive sensors. Data from one or more first non-invasive sensors can be utilized to calibrate one or more second non-invasive sensors. Non-invasive sensors can include, but are not limited to, an optical coherence tomography (OCT) sensor, a bio-impedance sensor, a tissue dielectric constant sensor, a plethysmograph sensor, or a Raman spectrometer.
Description
TECHNICAL FIELD

The present disclosure relates to blood glucose determination in biological tissues. Specifically, this disclosure relates to systems, methods, and apparatuses for harmonizing data from a plurality of non-invasive sensors to estimate blood glucose levels.


BACKGROUND

Monitoring of blood glucose (blood sugar) concentration levels has long been critical to the treatment of diabetes in humans. Current blood glucose monitors involve a chemical reaction between blood serum and a test strip, requiring an invasive extraction of blood via a lancet or pinprick. Small handheld monitors have been developed to enable a patient to perform this procedure anywhere, at any time. But the inconvenience of this procedure—specifically the blood extraction and the use and disposition of test strips—has led to a low level of compliance. Such low compliance can lead to serious medical complications. Thus, a non-invasive method for monitoring blood glucose is needed.


SUMMARY

The present disclosure describes example systems, methods, apparatuses, and medical devices for harmonizing data from a plurality of non-invasive sensors. In general, a physiological parameter can be determined by harmonizing data between two or more different types of non-invasive physiological sensors interrogating the same or proximate measurement sites. In some cases, data from one or more first non-invasive sensors can be utilized to identify one or more variables that are useful in one or more calculations associated with data from one or more second non-invasive sensors. In some cases, data from one or more first non-invasive sensors can be utilized to calibrate one or more second non-invasive sensors. Non-invasive sensors can include, but are not limited to, an optical coherence tomography (OCT) sensor, a bio-impedance sensor, a tissue dielectric constant sensor, a plethysmography sensor, or a Raman spectrometer.


For purposes of summarizing the disclosure, certain aspects, advantages and novel features are discussed herein. It is to be understood that not necessarily all such aspects, advantages or features will be embodied in any particular embodiment of the invention and an artisan would recognize from the disclosure herein a myriad of combinations of such aspects, advantages or features.





BRIEF DESCRIPTION OF THE DRAWINGS

The following drawings and the associated descriptions are provided to illustrate embodiments of the present disclosure and do not limit the scope of the claims.



FIG. 1 illustrates an example patient monitoring system that includes a plurality of physiological sensors.



FIG. 2 illustrates a block diagram of an example patient monitoring system.



FIG. 3A illustrates an example 3D OCT image obtained from a volar side of forearm skin.



FIG. 3B illustrates an example one-dimensional distribution of light intensity versus depth graph obtained by averaging scans of the image of FIG. 3A.



FIG. 4 illustrates example micro-invasive elements of a bioimpedance sensor.



FIG. 5 illustrates an example bioimpedance sensor.



FIG. 6 shows a graph illustrating various example light intensity signals acquired at a patient's wrist.



FIG. 7 illustrates a scaled view of the various example light intensity signals of FIG. 6.



FIG. 8 illustrates an approximation of an intensity of the fluorescence portion of the light intensity signals of FIG. 7.



FIG. 9 illustrates an approximation of an intensity of the isolated Raman with tissue absorption signals of FIG. 7.



FIG. 10 illustrates an approximation of an intensity of the isolated Raman with tissue absorption signals of FIG. 7.



FIGS. 11A-11C illustrate optical scattering differences in skin geometries among various age groups.



FIGS. 12A-12B illustrate an example sensor fusion apparatus configured with multiple sensing capabilities that interrogation of the same or a sufficiently proximate tissue site.



FIG. 13 illustrates an example reflectance sensor or probe.



FIG. 14 illustrates an environment that shows a hand of a user interacting with the example reflectance sensor of FIG. 13.



FIG. 15 illustrates an example physiological monitoring system.



FIGS. 16A-16C illustrate an example physiological monitoring apparatus.



FIG. 17 illustrates a flow diagram illustrative of an example routine for harmonizing data from a plurality of non-invasive sensors.



FIG. 18 illustrates a flow diagram illustrative of an example routine for harmonizing data from a plurality of non-invasive sensors.





While the foregoing “Brief Description of the Drawings” references generally various embodiments of the disclosure, an artisan will recognize from the disclosure herein that such embodiments are not mutually exclusive. Rather, the artisan would recognize a myriad of combinations of some or all of such embodiments.


DETAILED DESCRIPTION

Overview


Many non-invasive techniques for determining blood glucose have significant shortcomings, such as low accuracy (for example, less accuracy than invasive home monitors) and insufficient specificity of glucose concentration measurement. Accordingly, there is a need for an improved method to non-invasively monitor glucose. Systems and methods disclosed herein address various challenges related to non-invasively determining a patient's blood glucose level by harmonizing data from multiple non-invasive sensors. Each of the non-invasive sensors can interrogate the same or a similar tissue site of a patient, and variables identified using one or more sensors can be utilized to improve data from one or more other sensors. Using these data harmonization techniques, a glucose concentration measurement can be obtained.


In many instances, a single non-invasive sensor may lack the functionality to measure each of the parameters required for an accurate determination of an analyte concentration. As a result, many physiological monitoring techniques include estimations, such as those based on common assumptions, to compensate for the lack of known data. However, due to the sensitivity of analyte measurements, these estimations can result in inaccurate or unreliable determinations.


For example, Beer's Law (also known as the Beer-Lambert Law) relates the attenuation of light to properties of a material. In particular, Beer's law states that absorbance of a material is proportional to the concentrations of the attenuating species in the material sample. The relationship between these parameters is expressed in Equation 1 below:

A=ε*b*c  (Equation 1)

where A is the absorbance of the material at a given wavelength of light, ε is the molar absorptivity or extinction coefficient (L mol−1 cm−1), unique to each molecule and varying with wavelength, b is the length of the light path through the material (cm), and c is the concentration of an analyte of interest (mol L−1).


In many cases, the length of the light path through the material (sometimes referred to as the path length) is estimated. For example, a generic finger may be associated with a first estimated path length value, while a generic nose may be associated with a second path length value. However, every person has a unique tissue geometry, which can include, but is not limited to, unique skin structure or skin thickness. Furthermore, because tissue is not uniform throughout a person's body, even tissue sites that are close in proximity, such as two different measurements sites on a patient's finger, can have a different tissue geometry. As noted above, a specific tissue geometry of a particular tissue site can affect the path length value. Accordingly, a non-invasive physiological sensor can be configured to obtain skin geometry data, which can be utilized to calculate a path length associated with a tissue site. In addition or alternatively, the skin geometry data can be utilized to calibrate one or more sensors (for example, select a focal depth of Raman spectrometer), which can result in more accurate analytes measurements, such as blood glucose concentration measurements.


An optical coherence tomography, or OCT, sensor can be utilized to obtain tissue geometry information. OCT is an optical imaging technique using light waves that produce high-resolution imagery of biological tissue. OCT creates its images by interferometrically scanning in depth a linear succession of spots, and measuring backscattered light at different depths in each successive spot. The OCT data can be processed to present an image of the linear cross section. OCT data can be processed to determine tissue geometry information, such as skin geometry. For example, the OCT data can provide data regarding a thickness of one or more skin layers, such as the epidermis, the dermoepidermal junction, or the dermis.


In addition or alternatively, OCT data can be utilized to determine whether successive OCT measurements have occurred in the same or a different location. For example, one reason data harmonization between sensors is available relates to the specific optical profile of a particular tissue site. That is, a particular tissue site retains its specific optical profile, and a different measurement location may have a different optical profile. Thus, in many cases, to maintain data harmonization capabilities, each of the sensors should interrogate the same or a substantially proximate tissue site. One problem associated with interrogating the same or a substantially proximate tissue site relates to the subsequent placement of a sensor after it has been removed from the patient. To solve these and other problems, tissue geometry information associated with OCT data can be utilized to determine whether a later one of successive OCT measurements is taken at the same tissue site as a previous one of the successive OCT measurements.


A bio-impedance or tissue dielectric constant sensor can be utilized to obtain tissue geometry information. For example, bio-impedance or tissue dielectric constant data can provide information relating to one or more skin layers, a hydration of one or more skin layers, or a cellular structure of the tissue.


Raman spectroscopy has exhibited promise with respect to blood glucose detection, for example, due to its capability to gain information about the molecular constitution non-invasively. For example, features such as peaks of the Raman spectra are considered the Raman “fingerprints” of analytes such as glucose. Accordingly, using an isolated or semi-isolated Raman signal, the system can identify physiological data, such as information regarding a patient's blood glucose level.


For various reasons, it has been challenging to isolate a pure Raman signal from a signal obtained from a Raman spectrometer. For example, emission of fluorescence in tissue often overwhelms any signal collected from the Raman spectrometer, thereby hiding Raman features. In addition, attenuation of the signal due to absorption can further affect prediction of analytes using the collected signal. Furthermore, varying tissue geometries at tissue sites increases a difficulty in selecting a focal depth of the Raman spectrometer that will optimize a resolution of the Raman signal.


Systems and methods disclosed herein address one or more of these or other challenges by utilizing data associated with one or more sensors to calibrate or improve an accuracy of one or more other sensors. For example, a value for path length can be obtained from skin geometry data, which can improve a pulse oximetry sensor such as a near infrared (NIR), reflectance, or transmittance sensor. As another example, the present disclosure addresses various challenges related to leveraging the Raman scattering signatures for prediction of glucose by harmonizing data from a plurality of non-invasive physiological sensors. For instance, a focal depth of the Raman spectrometer can be selected based on tissue geometry data, which can improve the Raman spectrometer, and possibly increase an accuracy of a blood glucose measurement. Similarly, using data from one or more sensor, the Raman signal can be isolated by reducing or removing an effect of Fluorescence on a collected signal, or removing an effect of attenuation of the signal due to absorption.


System Overview



FIG. 1 illustrates an example patient monitoring system 100 that includes a patient monitor 102, a first sensor 104A, and a second sensor 104B. In addition, the patient monitoring system 100 can include one or more other sensors 104N. Sensors 104A, 104B, and 104N can interrogate tissue sites 106A, 106B, and 106N, respectively, of a patient. In some cases, tissue sites 106A, 106B, and 106N can be the same or substantially proximate tissue sites, while in other cases one or more of the tissue sites 106A, 106B, or 106N can be different. Sensor data from the sensors 104A, 104B, or 104N can be utilized to determine one or more physiological parameters or patient vitals. For example, the patient monitor 102 can receive a signal from the one or more of the sensors 104A, 104B, or 104N and can determine, based on the received signal(s), one or more physiological parameters or one or more measurements that can be used to determine a physiological parameter.


The sensors 104A, 104B, and 104N can each be the same type of sensors, or one or more of the sensors 104A, 104B, and 104N can be different from each other. For example, the sensors 104A, 104B, and 104N can include, but are not limited to, any combination of an optical coherence tomography (OCT) device, a spectrometer (for example, a Raman spectrometer), a plethysmograph sensor such as a pulse oximetry device (for example, a near infrared (NIR), reflectance and/or transmittance device), a pressure sensor, an electrocardiogram sensor, a bioimpedance sensor, or acoustic sensor, among other sensors.


Two or more of the sensors 104A, 104B, or 104N can be configured to interrogate the same tissue site. For example, two or more of the senor sensors 104A, 104B, or 104N can be positioned proximate each other such that they can interrogate the same tissue, such as a finger, a thumb, a thenar space, a hand, a wrist, a forearm, a nose, a limb, a head, an ear, a neck, an upper body, or a lower body. In addition or alternatively, two or more of the sensors 104A, 104B, or 104N can be configured to interrogate different tissue sites.


In some cases, one or more of the sensors 104A, 104B, or 104N can be integrated into an apparatus, such as an apparatus that is wearable by a user. For example, one or more of the sensors 104A, 104B, or 104N can be integrated into a glove that when worn by a user allows the sensor(s) to interrogate one or more tissue sites. Similarly, one or more of the sensors 104A, 104B, or 104N can be incorporated in or attached to various other apparatuses, including, but not limited to, a sock, a shirt, a sleeve, a cuff, a bracelet, a glove, or the like.


In some cases, data from a single sensor 104A, 104B, or 104N does not provide enough reliable information to determine certain physiological parameters. For example, a number of factors can affect an accuracy of sensor data including, but not limited to, patient movement, sensor placement, interference, the type of sensor being used, the expansion and contraction of the patient's vascular system, assumptions made during calculations, skin temperature, pressure, or the like. In addition or alternatively, the determination of some physiological parameters (for example, glucose concentration) may require more information than a single sensor can provide.


To solve this and other problems, the patient monitor 102 (or one or more of the sensors) can harmonize or compare data from two or more sensors, which can allow for a determination of more accurate or reliable data, or can allow for a determination of one or more additional physiological parameters, such as blood glucose concentration.


As one example, the patient monitor 102 receives a first signal from a first sensor 104A, the first signal corresponding to an interrogation of the first tissue site 106A by the first sensor 104A. Further, the patient monitor 102 receives a second signal from a second sensor 104B, the second signal corresponding to an interrogation of the second tissue site 106B by the second sensor 104B. Based on the first signal, the patient monitor 102 can make adjustments to modify the second sensor or the second measurement to improve the accuracy or reliability of the second sensor or the second measurement. For instance, adjustments can include, but are not limited to, adjusting an intensity, power, position, or timing of the second sensor 104b or adjusting values corresponding to the measurement of the second physiological parameter. For example, the patient monitor 102 can modify the second measurement or calculations for a physiological parameter (for example, introduce an offset, adjust assumed or estimated values, filter a signal, etc.) to account for information from the first sensor. In addition or alternatively, the patient monitor can adjust a confidence value associated with the first, second, or another measurement.


As described above, based at least in part on the first and second signals, the patient monitor 102 can determine a physiological parameter. The physiological parameter can be a value which may not be independently determinable from data from either of the first sensor or the second sensor alone. For example, data from the first sensor can be utilized to determine a path length, data from the second sensor can be utilized to determine an absorbance, and the physiological parameter can include a concentration of an analyte, such as glucose. As another example, data from the first sensor can be utilized to determine a path length or absorbance, the second sensor can correspond to a Raman spectrometer, and the physiological parameter can include a concentration of an analyte, such as glucose.


The patient monitor 102 can include a digital signal processor (DSP) that receives the signals generated by the one or more sensors 104A, 104B, or 104N (for example, through a front-end unit) and determines parameters, for example, those indicative of the physiological condition of the patient, using the received signals. The patient monitor 102 can, for example, determine physiological parameters corresponding to the patient, such as an amount of light absorbed, transmitted through, or reflected at a tissue site, path length (for example, distance that light travels through the material), concentration of an analyte, bioimpedance, tissue dielectric constant, pulse rate (PR), pulse pressure variation (PPV), pleth variability index (PVI®), stroke volume (SV), stroke volume variation (SVV), peripheral capillary oxygen saturation (SpO2), mean arterial pressure (MAP), central venous pressure (CVP), pulse pressure (PP), perfusion index (PI), total hemoglobin (SpHb®), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), oxygen content (SpOC®), or acoustic respiration rate (RRa®), among other parameters. In some aspects, the patient monitor 102 can derive or use one or more relationships (for instance, a set of linear equations) from two or more of the determined parameters. The patient monitor 102 can utilize the one or more relationships to determine the patient's glucose levels, systemic vascular resistance (SVR), CO, or arterial blood pressure (BP), among other parameters.


The patient monitor 102 can further compare or analyze one or more of the determined parameters (for instance, at least two of the determined parameters or one determined parameter and a previous or model parameter) to adjust how a parameter is measured or calculated to make the measured parameter more accurate or reliable, to adjust a sensor to make the measured parameter more accurate or reliable, to calculate, derive or determine an accuracy or a confidence value of a measured parameter, to isolate a parameter, or to determine another parameter based on the one or more parameters. The sensors, in addition to or alternatively than the patient monitor, can coordinate with each other to coordinate data or adjust calculations to enhance an accuracy or reliability of measurements. In addition or alternatively, the patient monitor 102 can use the data to increase an accuracy of one or more calculations, calculate a previously unknown or estimated physiological parameter, calibrate data, or compensate for various circumstances that might otherwise result in inaccurate or unreliable data.


Additional Implementations


The patient monitor 102 can be connected to one or more (for instance, three, four, five, or six) sensors, such as the sensors 104A, 104B, or 104N, that are detecting from a patient and use the signals received from the sensors to determine one or more physiological parameters including, but not limited to, glucose, SpO2, PPR, PVI® (for instance, via a palm, thumb or finger plethysmography sensor), SV, MAP, CVP, PP, or PI (for instance, via a palm, thumb or finger plethysmography sensor), among other parameters such as those described herein.


Moreover, the patient monitor 102 can utilize any of the techniques described herein to determine whether any measurement described herein (using any of the sensors described herein) is valid. The patient monitor 102 can be configured to show (for example, on a display) information about a valid or invalid measurement, activate an indicator light (such as an LED), trigger an alarm, adjust one or more sensors or parameters (for instance, based on a received sensor signal), or display any data.


The patient monitor 102 can wirelessly or using wires receive, via an input of the patient monitor 102, a signal from one of the sensors 104A, 104B, or 104N. The received signal may take various forms, such as a voltage, a current, or charge. An operational amplifier (op-amp) of the patient monitor 102 can increase the amplitude, as well as transform the signal, such as from a current to a voltage. An anti-aliasing filter (AAF) of the patient monitor 102 can then process of the output signal from the op-amp to restrict a bandwidth of the output signal from the op-amp to approximately or completely satisfy the sampling theorem over a band of interest. An analog-to-digital convertor (ADC) of the patient monitor 102 can convert the output signal from the AAF from analog to digital. The output signal from the ADC can then be sampled by a first processor of the patient monitor 102 at a relatively high speed. The result of the sampling can next be downsampled by a second processor of the patient monitor 102, which may be the same or different from the first processor, before waveform analysis may be performed by a DSP.



FIG. 2 illustrates a block diagram of an example patient monitoring system 200, which can be an embodiment of the patient monitoring system 100. The patient monitoring system 200 can include a patient monitor 202, a first non-invasive physiological sensor 204A, a second non-invasive physiological sensor 204B, or a third non-invasive physiological sensor 204C. Furthermore, it should be noted that fewer, additional, or different sensors may be included in patient monitoring system 200.


The sensors 204A, 204B, or 204C can respectively detect from tissue sites 206A, 206B, and 206C of a patient. Each of the sensor can measure from the same or a similar tissue site. For example, sensor 204A can take a measurement and sensor 204B can take a subsequent measurement on the same tissue or at the same location. This may allow the system to more easily harmonize the data from the sensors or use data from one sensor to improve data or calculation based on another sensor. The tissue sites 206A, 206B, and 206C can be different. As a non-limiting example, tissue site 206A can include a thenar space of a patient's hand, and tissue sites 206B, 206C include a thumb of the patient, such as a base of the thumb. It should be noted, however, that fewer, more or different sensors can be include in system 200.


The DSP 212A can communicate via drivers 216A with the plethysmography sensor 204A and receive via a front-end 214A one or more light intensity signals indicative of one or more physiological parameters of the patient or one or more measurements that can be used to determine one or more physiological parameters. For example, a signal can be indicative of an intensity of light reflected, refracted, scattered, absorbed, or transmitted at a tissue site. The drivers 216A can convert digital control signals into analog drive signals capable of driving emitters 209A to illuminate the tissue site 206A. For example, the light emitted by emitters 209A can have an infrared (IR), near infrared (NIR), red, ultra-violet (UV), visible, or other wavelength. The detector(s) 208A can, in turn, generate one or more composite analog light intensity signals responsive to light detected by the detector(s) 208A after attenuation, reflection, refraction, scattering, absorption, etc. at the tissue site 206A. The emitter(s) 209A or detector(s) 208A include a fiber-optic component for illumination and collection, respectively. For example, the emitter(s) 209A can be positioned on a tissue site 206A (for example, on top, on the bottom, on the side, etc.) and the detector(s) 208A can be positioned on an opposite portion of the tissue site 206A.


The front-end 214A can convert the one or more composite analog light intensity signals from the detector(s) 208A into digital data and input the digital data into the DSP 212A. The digital data from the front-end 216A can correspond to at least one of a plurality of physiological parameters as described herein. For example, the digital data from the front-end 216A can be representative of a change in the absorption of particular wavelengths of light as a function of the changes in the tissue site 206A resulting from pulsing blood.


The DSP 212A can include one or more data or signal processors configured to execute one or more programs for determining physiological parameters from input data. The DSP 212A can perform operations that include calculating or outputting one or more physiological measures, such as absorbance, path length, PVI® and other parameters described herein. The operations performed by the DSP 212A can be implemented in software, firmware or other form of code or instructions, or logic or other hardware, or a combination of the above.


The instrument manager 210 can communicate with one or more input or output devices 220. The one or more input or output devices 220 can include a user interface 222, controls 224, a transceiver 226, and a memory device 228.


The user interface 222 can include a numerical or graphical display that provides readouts of measures or parameters, trends and bar graphs of measures or parameters, visual indications of measures or parameters, visual indicators like LEDs of various colors that signify measurement magnitude, or device management interfaces, which can be generated by LEDs, LCDs, or CRTs, for example. The user interface 222 can include an audible output device that provides readouts or audible indications of measures or parameters. The user interface 222 can include one or more input devices like a keypad, touch screen, pointing device, voice recognition device, and computer that can be used to supply control or configuration data, such as initialization settings, from the user interface 222 to the instrument manager 210. In some implementations, the user interface 222 can be an interface for devices as well as users.


The controls 224 can be outputs to medical equipment, such as drug administration devices, ventilators, or fluid IVs, so as to control the amount of administered drugs, ventilator settings, or the amount of infused fluids. The patient monitor 202 can use the controls 224 to automatically treat the patient (for instance, provide fluid to the patient, provide medication to the patient, turn on a fan to cool the patient, or adjust a temperature of a room to heat or cool the patient) in response to determining that the patient may benefit from treatment.


The transceiver 226 via an antenna can transmit information about operation of the patient monitor 202 to an electronic device or receive control or configuration data for operating the patient monitor 202. The transceiver can, for example, communicate via a computer network or intermediary device or directly with the electronic device using electromagnetic radiation.


The memory device 228 can be used to store information about operation of the patient monitor 202. This information can, for example, include readouts of measures or parameters, trends and bar graphs of measures or parameters, visual indications or indicators.


The DSP 212B can receive via a front-end 214B one or more light intensity signals indicative of one or more physiological parameters of the patient. The drivers 216B can convert digital control signals into analog drive signals capable of driving emitters/detectors 220 to illuminate the tissue site 206B. For example, the light emitted by emitters/detectors 220 can be infrared (IR), near infrared (NIR), red, ultra-violet (UV), visible, or other wavelength. The emitters/detectors 220 can, in turn, generate one or more composite analog light intensity signals responsive to light detected by the emitters/detectors 220 light is reflected, refracted, scattered, absorbed, or attenuated at a tissue site 206B. The emitters/detectors 220 include a fiber-optic bundle that has illumination and detection fibers. In addition, for example, as described with respect to FIG. 1, the emitters/detectors 220 can be separate.


The front-end 214B can convert the one or more composite analog light intensity signals from the emitters/detectors 220 into digital data and input the digital data into the DSP 212B. The digital data from the front-end 214B can correspond to at least one of a plurality of physiological parameters, as described herein. The digital data from the front-end 214B can be representative of a change in the absorption/reflection of particular wavelengths of light as a function of the changes in the tissue site 206B resulting from pulsing blood.


The DSP 212B can include one or more data or signal processors configured to execute one or more programs for determining physiological parameters from input data. The operations performed by the DSP 212B can be implemented in software, firmware or other form of code or instructions, or logic or other hardware, or a combination of the above.


Sensor 204C includes a detector 208C, a light source 209C, a beam splitter 224C, and a reflector 222C. The light source 209C can emit light having an approximately equal wavelength, a spectrum of wavelengths, or a few different wavelengths, for example, two. For example, the wavelengths can be selected based on the absorption spectrum.


As illustrated, light beams from the light source 209C are split using the beam splitter 224C into reference arm light beams 230 and sample arm light beams 228. After the light beams 234 are split, the reference arm light beams 230 travel down the reference arm to interact with the reflector 222C, and the sample arm light beams 228 travel down the sample arm to interact with the tissue 206C, for example, from the base of a patient's thumb.


The tissue site 206C can absorb, reflect, scatter, or refract the sample arm light beams 228. Some of the sample arm light beams 228 are reflected back to the beam splitter 224C. The beam splitter 224C can direct at least some of the reflected sample arm light beams 228 to the detector 208C.


The light beams traveling down the reference arm interact with a reflector 222C and are reflected back to the beam splitter 224C. Similar to the reflected sample arm light beams 228, the reflected reference arm light beams 230 are also directed to the detector 208C by the beam splitter 224C. Reflected signals from the sample arm and reference arm and are presented to photodetector 208C for measurement.


The tissue volume with which the light interacts (referred to as the interaction volume) can be determined by the spot size of the imaging optics (surface area) and the coherence length of the light (depth). Thus, the reference arm can determine the depth within the interaction volume from which scattered light is measured. The patient monitor 200 uses the detected signals obtained from the interference of the reflected sample arm light beams 228 and the reflected reference arm light beams 230 to calculate tissue geometry data, such as a skin geometry of one or more skin layers.


Although not illustrated in FIG. 2, imaging optics can also be used to focus the sample arm light beams 228 prior to interacting with the tissue site 206C. Furthermore, the end of the sample arm and imaging optics can be placed in close proximity to the tissue site 206C. The reference arm and reflector 222 are configured such that appropriate wavelength and polarization selected such that the appropriate depth of the tissue is measured.


The DSP 212C can receive via a front-end 214C one or more signals indicative of one or more physiological parameters of the patient, such as path length. The drivers 216C can convert digital control signals into analog drive signals capable of driving emitters 209C to illuminate the tissue site 206C. The detectors 208C can, in turn, generate one or more composite analog signals responsive to light detected by the detectors 208C.


The front-end 214C can convert the one or more composite analog signals from the detectors 208C into digital data and input the digital data into the DSP 212C. The digital data from the front-end 216C can correspond to at least one of a plurality of physiological parameters, as described herein. The DSP 212C can include one or more data or signal processors configured to execute one or more programs for determining physiological parameters from input data. The operations performed by the DSP 212C can be implemented in software, firmware or other form of code or instructions, or logic or other hardware, or a combination of the above.


One or more of the components relating to signal acquisition or processing (for example, front end 214A, 214B, 214C, drivers 216A, 216B, 216C, DSP 212A, 212B, 212C, etc.) can be incorporated into one or more connecting cables, the sensors themselves, or are otherwise closer to the sensor sites. As such, the patient monitor 202 can include primarily the input or output devices 220 and the instrument manager 210, (if appropriate). In addition, some of the components are illustrated as separate units but can be combined. For instance, front end 214A, 214B, 214C can be combined into one or more front ends, drivers 216A, 216B, 216C, can be combined into one or more drives, DSP 212A, 212B, 212C can be combined into one or more DSPs, etc. By reducing the number of components included in the patient monitor 102, 202, the monitor can be smaller in size or more portable, which can be more convenient for home or “spot check” use.


Although not illustrated in FIG. 1 or 2 patient monitors 102, 202, or cables connecting the patient monitors to the sensors can further include one or more outputs that supply the signal(s) from one or more of the sensors to one or more other electronic devices for further processing. As one example, the signal(s) from one or more of the sensors can be output in parallel by one or more of the sensors or the cables that couple the one or more sensors to the patient monitor 102, 202. In another example, the patient monitors 102, 202 can include one or more outputs for outputting copy(ies) of the signal(s) from one or more of the sensors. The copy(ies) of the signal(s) can also be adjusted relative to the original(s) with filtering, scaling, or other changing prior to being provided to the one or more other electric devices.


Optical Coherence Tomography


Optical coherence tomography, or OCT, is an optical imaging technique using light waves that produces high-resolution imagery of biological tissue. OCT creates its images by focusing a beam of light into a medium and interferometrically scanning the depth of a linear succession of spots and measuring the absorption and/or the scattering of the light at different depths in each successive spot. In some cases, the data can be processed to present an image of the linear cross section of the medium scanned.


A light source can output a beam of light having a broad spectrum of wavelengths. The beam of light can be collimated and pass a beam splitter such that a portion of the beam of light is directed towards the tissue and a portion of the beam of light is directed toward a reference arm. The light can be either polarized or non-polarized. A polarizer located on one edge of the beam splitter can polarize the light linearly, elliptically, or circularly, as desired. The path length of the reference arm can be changed based on the desired measurement depth into the tissue. The wavelength can be centered at, for example, 1310 nm with a 50 nm bandwidth. In other cases, the wavelength can be 1060 nm with a 70 nm bandwidth. The light source can be selected to have a center wavelength anywhere between 400 nm and 1700 nm with a bandwidth of up to 150 nm. It is understood that different light sources with different bandwidths can be chosen to optimize penetration depth into the tissue and optimize the depth resolution of sensitivity to skin structures. The reflected light from the tissue can be collected using a converging lens and be directed back through the beam splitter to a photodetector where it is recombined with a portion of the reference arm beam to form an interference pattern. A processor can use the signals from the photodetector to render an image of the tissue.


OCT can provide a non-invasive method for identifying one or more characteristics of a tissue's structure. For example, OCT data (which can be referred to as tissue geometry data) can include an indication of a boundary between the main skin layers, such as the epidermis (outermost layer of the skin), the dermis (layer beneath the epidermis), or the hypodermis (layer directly below the dermis and serves to connect the skin to the underlying fibrous tissue of the bones or muscles). The epidermis is further divided into five, separate layers (Stratum Corneum, Stratum Lucidum, Stratum Granulosum, Stratum Spinosum, and Stratum Basale) and the dermis is divided into two, separate layers (the papillary dermis and the reticular dermis). In some cases, OCT data can provide an indication of a boundary between any of these layers. In addition or alternatively, OCT data can include can include an indication of a thickness of any of the epidermis, dermis, or hypodermis, or their individual layers.


For example, FIG. 3A illustrates an example 3D OCT image obtained from a volar side of forearm skin, and FIG. 3B illustrates an example one-dimensional distribution of light intensity vs. depth obtained by averaging Amplitude scans (A-scans) in the reconstructed OCT 3D image of FIG. 3A. The slope of the line of FIG. 3B is indicative of index of refraction of tissue. A difference in the index of refraction, or a difference in slope, can indicate a new skin or tissue layer because each layer may have a different index of refraction. As illustrated, the first peak 302 corresponds to the skin surface 302, and the second peak 308 corresponds to the dermoepidermal junction, which is the area of tissue that joins the epidermis 310 and the dermis layers (for example, the papillary dermis 304) of the skin. Accordingly, using OCT data, the system 200 can determine a thickness of one or more of various skin layers such as, but not limited to, the epidermis 310, the dermoepidermal junction, the papillary dermis 304, the reticular dermis 306, or the like.


In some cases, OCT data can provide an indication that an OCT sensor is interrogating an unfavorable tissue site. An unfavorable tissue site can include any tissue site that might provide distorted or inaccurate OCT data (relative to desired OCT data), such as tissue sites that include at least a portion of a hair follicle, a pore, a bone, a finger- or toe-nail, a pimple, a mole, a scar, a blister, a callous, debris, other skin imperfection, or the like.


A particular tissue site can retain its specific optical profile over time, and that optical profile can be different from another tissue site. Accordingly, to maintain data harmonization capabilities, it can be advantageous for sensors to interrogate the same or a substantially proximate tissue site. One problem associated with interrogating the same or a substantially proximate tissue site relates to the subsequent placement of a sensor after it has been removed from the patient or when it is shifted in some way from its original positioning. For example, a subsequent OCT measurement or set of measurements can occur minutes, hours, days, weeks, or some other period of time after the first measurement, and it can be unreasonable to require a patient to wear or interact with the OCT sensor for the duration of that period of time. Nonetheless, even though the OCT sensor has been separated from the patient or shifted from its original position, it can be advantageous for the subsequent OCT measurement(s) to occur at the same location as the first measurement. For example, as described herein, a first tissue site may have a different tissue structure, density, depth, hydration, analyte concentration, or the like than a second, different tissue site. Thus, if the OCT sensor is placed at the same location for each measurement, then previous calculations, determinations, or the like can be utilized, which can simplify any calibrations or corrections to sensor data, among other things.


To solve these and other problems, tissue geometry information associated with OCT data can be utilized to determine whether a subsequent placement of the OCT sensor allows the OCT sensor to interrogate the tissue site corresponding to the tissue site of the first OCT measurement(s). For example, a processor can compare the first tissue geometry data associated with the first OCT measurement(s) with the subsequent tissue geometry data associated with the subsequent OCT measurement(s). If the subsequent tissue geometry data does not correspond to the first tissue geometry data, then the processor can cause one or more actions to occur. For example, the processor can cause an output to indicate that the subsequent tissue geometry data does not correspond to the first tissue geometry data. In other words, the processor can cause an output to indicate that the subsequent placement of the OCT sensor is incorrect, or is different from the first OCT sensor placement, or the processor can cause an output to indicate a probe-off condition. In addition or alternatively, the processor can cause the OCT sensor to be re-positioned. For example, based on the comparison, the processor can suggest a new placement of the OCT sensor, which may more closely correspond to the first placement of the OCT sensor. In addition or alternatively, the processor can control a motorized component to re-position to the OCT sensor such that it more closely corresponds to the first placement of the OCT sensor. Still, in some implementations, the processor can calibrate other sensors based on the subsequent tissue geometry data, rather than the first tissue geometry data.


Alternatively, if the subsequent tissue geometry data does correspond to the first tissue geometry data, then the processor can cause one or more other actions to occur. For example, the processor can cause an output to indicate that the subsequent tissue geometry data does correspond to the first tissue geometry data. In other words, the processor can cause an output to indicate that the subsequent placement of the OCT sensor is correct, as compared to the first placement of the OCT sensor. In addition or alternatively, the processor can calibrate other sensors based on the first tissue geometry data or the subsequent tissue geometry data.


Bioelectrical Impedance (Bioimpedance)


Impedance can be characterized as a physical variable describing the resistance characteristics acting on an electric current. Bioelectrical impedance is based on the principle that tissues or fluids of a patient have different impedances, that is, opposition to the flow of the electric current, which in turn may be dependent on variables such as water and electrolyte content, to name a few. Using a bioelectrical impedance, analysis can be performed to examine electrical, capacitive, or resistive characteristics of tissue to provide information on a noninvasive basis.


Mathematically, bioelectrical impedance can be represented as a complex number including a real component (resistance) and an imaginary dimension (reactance). For example, the bioelectrical impedance can be calculated using the following equation below:

Z=R+jX=|Z|e  (Equation 2)

where R is resistance, X is reactance, |Z| is amplitude, and θ is phase.


A number of physiological characteristics or parameters can be calculated or estimated using determined bioelectrical impedance characteristics, such as water content, body cell mass (BCM), extra cellular mass (ECM), extracellular fluid (ECF), extracellular water (ECW), fat-free mass (FFM), fat mass (FM), total body water (TBW), electrolyte composition, cell membrane mass, cell membrane function and the like.


Biological tissues can have complex electrical impedance which is dependent, for instance, on the frequency of the electrical applied field or tissue cellular structure. Therefore, the electrical impedance of tissue is a function of its structure and it can be used to differentiate or determine characteristics of one or more layers to tissue.


The system can include a bioimpedance sensor configured to apply an electrical signal to the tissue, which can include one or more of various voltages, currents, frequencies (for example, 1 kHz to 2.5 GHz), or fields. In some cases, the path length of the signal can vary based on the applied electrical signal. For example, low frequency signals may primarily reflect the extracellular environment, while high frequency signals may reflect both the intra- and extracellular environment. In addition, the bioimpedance sensor can be configured to measure characteristics of the applied electrical signal as it passes (or after it has passed) through tissue. For example, the bioimpedance sensor can measure a voltage, current, frequency, magnetic field, etc., which can be indicative of a voltage difference across tissue or a biological impedance of a tissue, to name a few.


One or more properties of skin may disturb or disrupt bioimpedance measurements. For example, the stratum corneum can limit bioimpedance measurements. Accordingly, as illustrated in FIG. 4, the bioimpedance sensor can include a micro-invasive element 402 that is configured to penetrate the stratum corneum layer. For example, the bioimpedance sensor can include spikes or other elements that penetrate approximately 10-20 μm deep.



FIG. 5 illustrates an example bioimpedance sensor 502. The sensor 502 can include multiple channels of spiked regions configured to penetrate the skin. As shown, spacing between the channels can allow for shallow and deep penetration, such that the bioimpedance sensor 502 can measure impedance at various depths, such as Depths 1a, 2a, 2b, 3a, or 4a.


Using information from the bioelectric sensor(s) 502, the system 200 can determine information about the tissue geometry. For example, based on bioelectric sensor data, the system can determine a cellular structure of the tissue, which may affect various physiological parameters, such as path length or absorption. In addition, based on bioelectric sensor data, the system can determine information related to hydration of the skin or tissue. For example, water content can be directly related to skin thickness. As described herein, in some cases, the system can select a focal depth of the Raman spectrometer based at least in part on tissue geometry data.


Tissue Dielectric Constant


In addition or alternatively to bioimpedance or OCT, the system can utilize one or more tissue dielectric constant sensors to determine various tissue geometries or tissue information, including, but not limited to a dielectric constant of tissue. For example, the system 200 can include a plurality of probes for different measuring depths, such as 0.5 mm, 1.5 mm, 2.5 mm, and 5 mm effective depths, and the system can determine a dielectric value at each of the different depths. In addition or alternatively, the system 200 can include one or more probes that are each configured to measure at different depths, such as 0.5 mm, 1.5 mm, 2.5 mm, and 5 mm effective depths, and the system can determine a dielectric value at each of the different depths. The dielectric value can correlate with water content, which can be tied to tissue structure.


Accordingly, the tissue dielectric constant can provide information which can be combined with other sensor information (for example, OCT, bioimpedance, reflectance or transmission measurements, Raman measurements) to determine more accurate physiological measurements, such as blood glucose levels. For example, the bioimpedance or tissue dielectric constant data can provide information that correlates with local tissue hydration, or can provide information about different skin layers or cellular structure information. Furthermore, bioimpedance or tissue dielectric constant sensors can provide real-time measurements that can provide information about physiological “noise” within the tissue, which can be used to calibrate other measurements or calculations. As described herein, in some cases, the system can select a focal depth of the Raman spectrometer based at least in part on tissue geometry data.


Raman Spectroscopy


The Raman effect is a light-scattering phenomenon that can provide insight as to one or more characteristics of an analyte in a sample. When light irradiates a tissue, a fraction of the light is scattered, meaning it emerges in directions other than that of the incident (incoming) beam. Most of this scattered light, generally referred to as Rayleigh scattering, emerges at the original frequency (f0) and wavelength of the incident beam. A small portion of the scattered light, however, emerges at some shifted frequency (fs) that is different from, and usually lower than, the original frequency (f0) and has wavelengths different from that of the incident light. The process leading to this small portion of the scattered light is termed the Raman effect or Raman scattering.


Raman scattering can occur with a change in vibrational or rotational energy of a molecule. Accordingly, the Raman spectra can contain information about the specific chemical substance in the irradiated tissue. For example, Raman scattering yields a set of characteristic peaks in a spectrum, which is a “fingerprint” of a specific chemical substance. Therefore, Raman has high specificity in glucose measurements.


Raman spectroscopy has exhibited promise with respect to blood glucose detection, for example, due to its capability to gain information about the molecular constitution non-invasively. For example, features (such as peaks) of the Raman spectra are considered the Raman “fingerprints” of analytes, such as glucose. Accordingly, using an isolated or semi-isolated Raman signal, the system can identify physiological data, such as information regarding a patient's blood glucose level. However, for various reasons, it has been challenging to isolate a pure Raman signal from a signal obtained from a Raman spectrometer.


The signal collected through Raman spectroscopy is based at least in part on the collection optics and the focal distance/depth of the optics into the tissue. In some cases, the system can use data from one or more sensors to select an appropriate focal depth. For example, a focal depth can be selected that may provide a high or the highest resolution of the Raman or collected signal. In addition or alternatively, a focal depth can be selected that will allow the Raman spectrometer to focus on a particular location of the tissue, such as the capillary beds. For example, OCT, bioelectrical impedance, or tissue dielectric constant measurements may provide tissue geometry data (for example, structural and functional information) that can be used to select a focal depth into the tissue. For example, the selection can be based at least in part on a water content of a portion of the tissue, a thickness of one or more skin layers, or a particular location of tissue, such as the capillary beds.


Although complex, an approximation of a measurement obtained from a Raman spectrometer can be determined using one or more of the following equations:

I1=I0e−A1  (Equation 3)
R0=RAI1  (Equation 4)
F0=ΦI1  (Equation 5)
I2=Σ((R0+F0)e−A2)  (Equation 6)

where I0 is an intensity of excitation light, I1 is an intensity of scattered light, A1 is a first interrogation volume, RA represents Raman activity, R0 is an intensity Raman scattering at a specific wavelength of light, F0 is an intensity of Florescence at the specific wavelength of light, Φ represents quantum efficiency, A2 represents a second interrogation volume, and I2 is an intensity of measured light. From these relationships, it can be seen that the intensity of measured light (I2) is dependent on the intensity of Raman scattering (R0), the intensity of Fluorescence (F0), or the second interrogation volume (A2), among other things. Due to the nature of the Raman spectroscopy, the intensity of Raman scattering (R0) is often of very low intensity. In various aspects, the system can reduce or remove an effect of Fluorescence or absorption on the measured signal, thereby isolating or improving the Raman signal (R0).


Fluorescence


A challenge in the implementation of Raman spectroscopy to obtain physiological data is the emission of fluorescence. Accordingly, if fluorescence is generated, it often overwhelms the Raman signal, effectively hiding the Raman features. Thus, in some cases, is can be advantageous to isolate the Raman signal.



FIG. 6 shows a graph 600 illustrating various example light intensity signals acquired at a patient's wrist. In this example, the y-axis corresponds to arbitrary intensity units, while the x-axis corresponds to a wavenumber shift (in cm−1). Because the Raman signal is dependent on the excitation wavelength, it can be convenient to use wavenumber to indicate the change of wavelength compared to excitation wavelength. Wavelength change is also photo energy change that is often described by wavenumber change in the frequency domain, because wavenumber is used to describe wavelength in the frequency domain. Wavelength can convert to wavenumbers by dividing one centimeter by wavelength.


As described herein, the light intensity signal acquired from a Raman spectrometer is influenced by the emission of florescence. For example, fluorescence is often much more intense than Raman scattering, and fluorescence can overwhelm or mask a Raman measurement in the light intensity signal. This can be seen in each of the signals of the graph 600. For example, the overall shape of each signal of the graph 600 is attributable to the fluorescence, while the subtle oscillations of each signal are attributable to Raman. Because the fluorescence tends to mask the Raman spectrum, it can be desirable to remove or reduce an effect of the fluorescence on the light intensity signal.


Various techniques for removing or reducing an effect of the fluorescence on the light intensity signal are known, including, but not limited to, confocal configuration, photobleaching, chemical bleaching, deployment of laser excitation at longer wavelengths, filtering with respect to pixel frequency (or wavenumber frequency), signal decomposition by various forms of component subtraction from a priori information, photobleaching curve fitting to subtract away an approximated fluorescence signal, frequency offset Raman methods, spatial offset Raman methods, or the like.


For example, irradiating tissue with intense laser light for a long period of time (sometimes referred to as photobleaching) can reduce a level of fluorescence emission in the light intensity signal, thus increasing the signal to noise (S/N) ratio of a Raman measurement. That is because the fluorescence signal of skin will decrease over time (experiencing an exponential decay) as a source is continually shining, while a Raman signal will not change. By looking at the exponential decay (in time) of photobleaching, the system can obtain a fluorescence approximation by curve fitting.


As another example, a system can use a first excitation wavelength to characterize the fluorescence, and then can subtract the fluorescence from a signal of a second excitation wavelength to isolate the Raman. For example, a location of peaks of the fluorescence emission are independent of excitation wavelength, whereas a location of peaks and compactness of emission of Raman spectra are dependent on excitation wavelength. Using this information, the system can remove or reduce an effect of fluorescence emission in the light intensity signal. Fluorescence can also be removed by taking sequential measurements of the tissue over time. For example, the fluorescence signal can be isolated by the change of the measured spectrum overtime.



FIG. 7 illustrates a scaled view of the various example light intensity signals of FIG. 6. As described herein with respect to FIG. 6, the light intensity signals are influenced by, among other things, fluorescence, Raman scattering, and tissue absorption. For example, the light intensity signals can include a significant fluorescence baseline.



FIG. 8 illustrates an approximation of an intensity of the fluorescence portion 800 of the light intensity signals 700 of FIG. 7. This approximation of fluorescence can be determined using various techniques, such as those described herein. The system can utilize photobleaching curve fitting to subtract away an approximated fluorescence signal. For example, over time, the Raman signal (R0) will remain constant while the fluorescence F0 will experience an exponential decay. By looking at the exponential decay (in time) of photobleaching, the system can obtain a fluorescence approximation by curve fitting.



FIG. 9 illustrates an approximation of an intensity of the isolated Raman with tissue absorption signals of FIG. 7. In this example, at least some of the effect of florescence (for example, illustrated in FIG. 8) has been removed or reduced. Accordingly, the graph 700 of FIG. 7 can be approximately equal to the Raman and tissue absorption portion (for example, the Σ(R0e−A2) portion of Equation 6) of the light intensity signals of FIG. 6. As can be seen from a comparison of FIGS. 7 and 9, the presence of fluorescence in the light intensity signals 700 can mask many of the Raman features, such as the peaks, valleys, amplitude, compaction, and the like. By removing or reducing the presence of fluorescence in the light intensity signals 700, the system can isolate the Raman signal.



FIG. 10 illustrates an approximation of an intensity of the isolated Raman with tissue absorption signals of FIG. 7. In this example, the signal of graph 900 of FIG. 9 has been filtered to reduce or remove at least some of a remaining effect of florescence. For example, the system can filter the signal using a band pass or high pass filter.


Absorption


Another challenge in the implementation of Raman spectroscopy to obtain physiological data is the attenuation of the signal due to absorption. In some cases, the Raman signal can be isolated or improved by reducing or removing an effect of absorption on the measured signal. For example, sensor data from one or more sensors, such as a near infrared (NIR), reflectance, transmittance, or pulse oximetry sensor, can be utilized to determine absorption, which can be removed from one or more other measurements, such as a Raman measurement.


An effect of the tissue absorption (for example, the e−A portion of Equation 6) may be removed or reduced in various ways. For example, the absorption data, transmission data, reflectance data, or the like may be determined using data from one or more sensors, such as, but not limited to, a near infrared (NIR), reflectance, transmittance, or pulse oximetry sensor. Based on the sensor data, a processor can further process the signal (for example, signal 900 or 1000) to reduce or subtract an effect of the attenuation of the signal due to absorption.


Tissue Geometry


Tissue geometry can vary greatly between individuals. For example, skin structure or skin thickness can vary across races, ages, or the like. Even individuals having similar demographics can have different skin geometries. FIGS. 11A-11C illustrate optical scattering differences in skin geometries among various age groups. FIG. 11A corresponds to 20-39 year olds, FIG. 11B corresponds to 40-59 year-olds, and FIG. 11C corresponds to 60-79 year-olds. In these examples, the x-axis corresponds to a compaction of the skin and is measured from 0 to 200 units, where one unit is 3 μm, and the y-axis corresponds to brightness (for example, backscattered intensity) of the skin and is measured from 0 to 800 AU (absorbance units). As evidenced by these graphs 1100A, 1100B, 1100C, the general skin structure or thickness is not constant throughout the population.


Tissue geometry can be can also vary greatly between tissue sites of a particular individual. For example, each of a finger, a thumb, a thenar space of a hand, a wrist, a forearm, a nose, an ear, a neck, or other tissue site can have a different skin geometry. Even tissue sites that are in close proximity, such an upper part of a finger and a lower part of a finger, can have a different skin geometry.


Example Sensor Fusion Apparatus


A patient monitoring system such as systems 100 or 200 can include multiple noninvasive sensors. At least one sensor can be configured to provide tissue geometry information, and the system can utilize tissue geometry data to calibrate one or more other sensors or otherwise improve data obtained by the one or more other sensors. Techniques for utilizing sensor data to improve or calibrate another sensor can be referred to as data harmonization or sensor fusion.


As described herein, data acquired by a sensor can be a function of, or at least affected by, the tissue geometry of the particular tissue site that the sensor is interrogating. For example, tissues having a different geometry can result in a different optical profile. Consequently, data obtained from a first sensor at a first tissue site might not be useful for calibrating or improving a sensor that is interrogating a second, different tissue site. Accordingly, to accurately or reliably harmonize data between sensors, it can be helpful for each of the multiple sensors to acquire data associated with the same or a similar tissue site. In other words, it can be advantageous for each of the multiple sensors to interrogate the same or a sufficiently proximate tissue site so that a variable or other information determined using data from one sensor can be used to improve one or more others sensors. The present disclosure can provide for an apparatus configured allow multiple sensors to interrogate the same or a sufficiently proximate tissue site.



FIGS. 12A-12B illustrate an example sensor fusion apparatus 1200 configured with multiple sensing capabilities for interrogation of the same or a sufficiently proximate tissue site. As shown, the apparatus 1200 can include an OCT sensor or lens 1202, a Raman spectrometer 1204, a pulse oximetry sensor 1206, and a bioimpedance sensor 1208.


As illustrated in FIG. 12B, the apparatus 1200 can include a cylindrical housing 1210. In the illustrated example, the sensor side of the apparatus 1200 can be positioned on or proximate to a tissue site of a patient, and one or more of the an OCT sensor 1202, a Raman spectrometer 1204, a pulse oximetry sensor 1206, and a bioimpedance sensor 1208 can be configured to interrogate the same or a sufficiently proximate tissue site. Although at least some of the sensors are illustrated as being configured to obtain data via reflectance technologies, in some cases one or more sensors are configured to obtain data via transmittance or other technologies.


Example Reflectance Sensor



FIG. 13 illustrates an example reflectance plethysmography sensor or probe 1300. The reflectance sensor or probe 1300 includes a light source 1302 at its center and seven detector channels 1304 surrounding the light source 1302. The light source 1302 and emit light to illuminate a tissue site, and one or more of the channels 1304 can detect the light after it interacts with the tissue site. In some cases, the one or more of the channels 1304 can generate a composite analog light intensity signal responsive to the detected light. In some cases, light source 1302 or the channels 1304 can include a fiber-optic component for illumination or collection. For example, the light source 1302 can include a fiber bundle.



FIG. 14 illustrates an environment 1400 that shows a hand of a user interacting with the example reflectance sensor 1300 of FIG. 13. The reflectance sensor 1300 can be configured to interact with one or more of the various tissue sites described herein. For example, as illustrated, the reflectance sensor 1300 can be positioned to interrogate at a metacarpal bone 1306. The metacarpal bone 1306 forms the intermediate part of the skeletal hand located between the phalanges of the fingers and the carpal bones of the wrist which forms the connection to the forearm.


Example Patient Monitoring



FIG. 15 illustrates an example physiological monitoring system 1500, which can be an embodiment of the patient monitoring system 100 or 200. As illustrated in FIG. 15, the system 1500 can include a first sensor 1504A and a second sensor 1504B. In some implementations, the first sensor 1504A, the second sensor 1504B, or another sensor can be integrated into an apparatus, such as a wearable apparatus like a glove, a sock, an armband, a headband, a chest strap, etc.


The first sensor 1504A can be similar to sensor 204A, as described herein with respect to FIG. 2. For example, the sensor 1504A can include an emitter and detector. The emitter can emit light (for example, of an infrared or near-infrared wavelength) to illuminate a tissue site of a patient. In this example, the tissue site corresponds to a thenar space of the patient's hand. However, other tissue sites are contemplated. As the light interacts with (for example, passes through) the thenar space of the hand, some light may absorbed, reflected, refracted, or the like. The detector can receive or generate a signal responsive to the light detected by the detector after it interacts with the thenar space of the hand. The signal generated by the detector can be received by a processor (not shown), which can determine one or more various physiological parameters, such as an absorbance of the tissue based at least in part on the received signal.


The second sensor 1504B can be similar to sensor 204C, as described herein with respect to FIG. 2. For example, the second sensor 1504B can include a light source and a detector. The emitter can emit light (for example, of an infrared or near-infrared wavelength) to illuminate a tissue site of a patient. As the light interacts with (for example, reflects off) the thenar space of the hand, some light may absorbed, transmitted through, reflected, refracted, or the like. The detector can receive or generate a signal responsive to the light detected by the detector after it interacts with the hand. The signal generated by the detector can be received by a processor (not shown), which can determine one or more various physiological parameters, such as a transmittance of the tissue based at least in part on the received signal.



FIGS. 16A-16C illustrate an example physiological monitoring apparatus 1600. As illustrated, a user can place his or her arm in the apparatus 1600, such that two or more sensors of the apparatus 1600 can interrogate tissue of the arm. The two or more sensors can correspond to any of the sensors described herein. For example, the two or more sensors can interrogate the same or a different tissue site of the arm. In some cases, the apparatus 1600 can be miniaturized and integrated into a wearable apparatus, such as a glove, a sock, an armband, a headband, a chest strap, etc.


Example Data Harmonization



FIG. 17 illustrates a flow diagram illustrative of an example routine for harmonizing data from a plurality of non-invasive sensors. One skilled in the relevant art will appreciate that the elements outlined for routine 1700 may be implemented by one or many computing devices/components, such as in hardware, with a front end component, with a sensor interface, or with a processor, such as one or more processors housed in a patient monitor, one or more remote processors, one or more processors housed in the sensors, etc. Accordingly, although routine 1700 has been logically associated as being generally performed by a processor, the following illustrative embodiments should not be construed as limiting.


At block 1702, a processor can receive data from one or more first noninvasive sensors. The one or more first noninvasive sensors can include an optical coherence tomography (OCT) sensor. As described herein, the OCT sensor can provide a non-invasive method for identifying one or more characteristics of a tissue's structure. The data received by the processor from the OCT sensor can include OCT data, which can be referred to as tissue geometry data.


In addition or alternatively, the one or more first noninvasive sensors can include a bioimpedance sensor or a tissue dielectric constant sensor. As described herein, the bioimpedance sensor or tissue dielectric constant sensor can provide a non-invasive method for identifying one or more characteristics of a tissue's structure. The data received by the processor from the bioimpedance sensor or tissue dielectric constant sensor can include bioimpedance data, which can include tissue geometry data, hydration data, or the like.


At block 1704, a processor can receive data from one or more second noninvasive sensors. The one or more second noninvasive sensors can include a pulse oximetry sensor, such as a reflectance or transmission sensor. As described herein, the pulse oximetry sensor can provide a non-invasive method for identifying or more of various physiological parameters.


At block 1706, a processor can receive data from one or more third noninvasive sensors. The one or more second noninvasive sensors can include a Raman spectrometer. As described herein, the Raman spectrometer can provide a non-invasive method for identifying or more of various physiological parameters.


At block 1708, the processor can harmonize the data received from two or more of the non-invasive sensors. By harmonizing the data from two or more non-invasive sensors, the system may be able to compensate for circumstances that might otherwise result in inaccurate or unreliable data. For example, using skin geometry information (for example, skin thickness), the processor can weight or prioritize longer or shorter path length detectors. In addition or alternatively, the various sensor data, such as skin geometry information, can allow the processor compensate for sensor or probe placement. For example, a location, coupling, or pressure can be compensated by the processor by adjusting path length, which can be determined from the various sensor data, such as skin geometry information. Similarly, the processor can utilize the various sensor data, such as skin geometry information, to detect drift or motion at the tissue site.


As a non-limiting example, the data received at block 1702 from the OCT sensor, the bioelectrical impedance sensor, or the tissue dielectric constant sensor can include tissue geometry information. Based at least in part on the tissue geometry data, the processor can determine a path length corresponding to a tissue site interrogated by the one or more first noninvasive sensors. In some cases, the determined path length can be utilized with the pulse oximetry sensor to determine a concentration of an analyte, such as blood glucose. For example, based on the data received at block 1704 from the one or more second noninvasive sensors, the processor can determine an absorbance corresponding to a tissue site interrogated by the one or more second noninvasive sensors. Using one or more relationships derived from Beer's law (Equation 1), the concentration, c, of one or more analytes can be determined using the absorbance, A, determined from the pulse oximetry sensor data, and the path length, b, determined from the tissue geometry data.


As another non-limiting example, the processor can utilize the tissue geometry data to select a focal depth or focal length, wavelength, refractive index, or other parameter associated with the Raman spectrometer. For example, the tissue geometry data can provide an indication of a particular location of tissue, such as the capillary beds. The processor can select a focal depth or focal length of the Raman spectrometer such that the Raman spectrometer can focus on this particular location. As a result, the processor can determine a more accurate indication of glucose concentration from the Raman signal.


As another non-limiting example, the processor can utilize the pulse oximetry data to filter data received from a Raman Spectrometer to isolate a Raman Spectra. For example, as described herein, a direct measurement of glucose can be determined based on features of the isolated Raman signal. Using the pulse oximetry data, the processor can filter out an effect of absorbance on the Raman Spectra.


In addition or alternatively, using the various sensor data, the processor can create calibrations for one or more individuals. For example, although skin geometry may vary between individuals, one or more groups of individuals may have similar skin geometries, which can allow for more accurate physiological parameter estimations of for individuals in those groups. For example, using the various sensor data, such as the skin geometry, Raman, or NIR data, the processor can determine calibrations for different groups, such as different skin populations, different ages, or the like.


The various blocks of process 1700 described herein can be implemented in a variety of orders, and that the system can implement one or more of the blocks concurrently or change the order, as desired. For example, the system 100 can concurrently receive any of the sensor data, or receive the sensor data in any order. Similarly, the system can make one or more calculations or determinations in any order, such as before or after receiving data from one or more sensors.


It will be understood that any of the first, second, or third sensors can interrogate the same or a different tissue site. Furthermore, it will be understood that fewer, more, or different blocks can be used as part of the routine 1700. Likewise, fewer, more, or different sensors can be used by the system. For example, the routine 1700 can include blocks for receiving data associated with additional non-invasive sensors or determining various other physiological parameters. Furthermore, the routine 1700 can include causing a display to display one or more of various indications of the any other the sensor data, calculations, or determinations.



FIG. 18 illustrates a flow diagram illustrative of an example routine for harmonizing data from a plurality of non-invasive sensors. One skilled in the relevant art will appreciate that the elements outlined for routine 1800 may be implemented by one or many computing devices/components, such as in hardware, with a front end component, with a sensor interface, or with a processor, such as one or more processors housed in a patient monitor, one or more remote processors, one or more processors housed in the sensors, etc. Accordingly, although routine 1800 has been logically associated as being generally performed by a processor, the following illustrative embodiments should not be construed as limiting.


At block 1802, the process 1800 can receive tissue geometry data from a first noninvasive sensor. As described herein, the first non-invasive sensor can include a combination of one or more of an OCT sensor, a bioimpedance sensor, a tissue dielectric constant sensor, or any other sensor configured to measure or determine tissue geometry data. The tissue geometry data can include various information corresponding to the skin, fluids, bones, or the like. For example, tissue geometry data can include, but is not limited to, a thickness of one or more skin layers (for example, the epidermis, the dermoepidermal junction, the papillary dermis, the reticular dermis, etc.), cellular structure information, a water content of a portion of the tissue, etc.


At block 1804, the process 1800 can calibrate a Raman Spectrometer based at least in part on the tissue geometry data received at block 1802. For example, the tissue geometry data can provide insight about the tissue site, which can allow the process 1800 to optimize one or more settings of the Raman spectrometer. For example, based at least in part on the tissue geometry data, the process 1800 can select a focal depth or focal length, wavelength, refractive index, or other parameter associated with the Raman spectrometer. By adjusting one or more settings or positioning of the Raman spectrometer based on the tissue geometry data, the process can enhance a signal received by the Raman spectrometer. For example, the new settings can increase the collection efficiency, the resolution, the signal-to-noise ratio, or the like of the Raman signal.


At block 1806, the process 1800 can receive absorption, transmission, reflectance, or other data from a second noninvasive sensor. As described herein, the second non-invasive sensor can include one or more of a pulse oximetry sensor, a reflectance sensor, a transmittance sensor, or another sensor from which absorption, transmission, reflectance, or other tissue related data can be determined. In some cases, the second noninvasive sensor can include a light source configured to emit light and a detector and configured to detect light. Depending on the type of sensors, the detected can be configured to detect light after having it has passed through, reflected, refracted, or scattered at a tissue site of a patient. In some cases, the tissue site corresponding to the second sensor (for example, the tissue site at which the second sensor takes a measurement) is the same tissue site (or within a close proximity) as the tissue site of the second sensor. For example, the first and second sensors can be configured to interrogate the tissue site at different periods of time. However, in some cases, the first and second sensors can be configured to interrogate different tissue sites.


At 1808, the process 1800 can receive a Raman signal corresponding to the Raman spectrometer. As described herein, the light intensity signal acquired from a Raman spectrometer is influenced by the emission of florescence.


At block 1810, the process 1800 can determine an isolated Raman signal by reducing or removing an effect of fluorescence or an effect of absorption from the Raman signal received at block 1808. As described herein, fluorescence can overwhelm or mask a Raman measurement in the light intensity signal. As such, the process 1800 can use one or more techniques described herein to reduce or remove an effect of the fluorescence on the Raman signal. In addition or alternatively, the process 1800 can reduce or remove an effect of absorption on the Raman signal. For example, using the absorption data acquired at block 1806, the process 1800 can filter, subtract, reduce, or remove an effect of absorption on the Raman signal. By reducing or removing an effect of fluorescence or an effect of absorption from the Raman signal, the process 1800 can determine an isolated (or semi-isolated) Raman signal.


At block 1812, the process 1800 can determine data corresponding to one or more analytes based at least in part on the isolated Raman signal. For example, features of the Raman spectra (such as peaks, valleys, concentrations, etc.) can corresponds to analytes such as glucose. Accordingly, using the isolated or semi-isolated Raman signal, the system can identify physiological data, such as information regarding a patient's blood glucose level. Thus, the process 1800 can harmonize data from various non-invasive sensors to non-invasively determine a patient's blood glucose level, or other analyte.


It will be understood that the various blocks of process 1800 described herein can be implemented in a variety of orders, and that the system can implement one or more of the blocks concurrently or change the order, as desired. Furthermore, it will be understood that fewer, more, or different blocks can be used as part of the routine 1800. For example, fewer, more, or different sensors can be used by the system. Furthermore, the routine 1800 can include blocks for receiving data associated with additional non-invasive sensors or determining various other physiological parameters. Furthermore, the routine 1800 can include displaying one or more of various indications of the any other the sensor data, calculations, or determinations.


Further Examples

Various example features can be found in the following clauses, which can be implemented together with any combination of the features described above:


Clause 1: A physiological monitoring system configured to determine a physiological parameter by harmonizing data between two or more different types of non-invasive physiological sensors interrogating the same or proximate measurement sites, the physiological monitoring system comprising:

    • a first non-invasive sensing device of a first type configured to interrogate a tissue site of a patient and generate a first signal indicative of first physiological data associated with the tissue site;
    • a second non-invasive sensing device of a second type that is different from the first type configured to interrogate the tissue site of the patient and generate a second signal indicative of second physiological data associated with the tissue site; and
    • one or more processors in communication with the first and second non-invasive sensing devices, the one or more processors configured to:
      • receive the first signal indicative of the first physiological data;
      • receive the second signal indicative of the second physiological data; and
      • determine a physiological parameter based at least in part on the first and second signals.


Clause 2: The system of Clause 1, wherein the first non-invasive sensing device comprises one or more of an optical coherence tomography (OCT) sensor, a bioimpedance sensor, or a tissue dielectric constant sensor.


Clause 3: The system of any of the previous clauses, wherein the first physiological data comprises tissue geometry data corresponding to the tissue site.


Clause 4: The system of any of the previous clauses, wherein tissue geometry data comprises at least one of data corresponding to one or more of a thickness of one or more layers of skin of the tissue site, cellular structure information associated with the tissue site, or a water content associated with the tissue site.


Clause 5: The system of any of the previous clauses, wherein the first non-invasive sensing device comprises a plethysmography sensor.


Clause 6: The system of any of the previous clauses, wherein the plethysmography sensor comprises one or more of a pulse oximetry sensor, a transmission plethysmography sensor, or a reflectance plethysmography sensor.


Clause 7: The system of any of the previous clauses, wherein the plethysmography sensor comprises:


at least one emitter configured to emit light, and


at least one detector configured to:

    • detect the light after interaction with the tissue site, and
    • generate the second signal responsive to the detected light.


Clause 8: The system of any of the previous clauses, wherein the first non-invasive sensing device and the second non-invasive sensing device are configured to simultaneously interrogate the tissue site.


Clause 9: The system of any of the previous clauses, wherein the first non-invasive sensing device and the second non-invasive sensing device are configured to interrogate the tissue site at distinct and different time periods.


Clause 10: The system of any of the previous clauses, wherein the second non-invasive sensing device comprises a Raman spectrometer.


Clause 11: The system of any of the previous clauses, wherein the second physiological data corresponds to Raman spectra associated with the tissue site.


Clause 12: The system of any of the previous clauses, wherein the one or more processors are further configured to determine an isolated Raman signal by reducing or removing at least one of an effect of fluorescence or an effect of absorption from the second signal.


Clause 13: The system of any of the previous clauses, wherein the one or more processors are further configured to determine the isolated Raman signal based at least in part on the first signal.


Clause 14: The system of any of the previous clauses, wherein the one or more processors are further configured to determine a path length associated with the tissue site based at least in part on the first signal, wherein the determination of the physiological parameter is based at least in part on the determined path length.


Clause 15: The system of any of the previous clauses, wherein the one or more processors are further configured to determine an absorption of light of the tissue site based at least in part on the second signal, wherein the determination of the physiological parameter is based at least in part on the determined absorption of light.


Clause 16: The system of any of the previous clauses, wherein physiological parameter comprises a concentration of one or more analytes.


Clause 17: The system of any of the previous clauses, wherein physiological parameter comprises a blood glucose concentration associated with the tissue site.


Clause 18: The system of any of the previous clauses, wherein one or more processors are further configured to calibrate the second non-invasive sensing device based at least in part on the first signal.


Clause 19: The system of any of the previous clauses, wherein second non-invasive sensing device comprises a Raman spectrometer, wherein to calibrate the Raman spectrometer, the one or more processors are configured to select at least one of a focal depth, a focal length, a wavelength, or a refractive index, associated with the Raman spectrometer.


Clause 20: The system of any of the previous clauses, wherein the tissue site comprises a thenar space of a hand.


Clause 21: The system of any of the previous clauses, wherein the tissue site comprises an area associated with a metacarpal bone.


Clause 22: A method for determining a physiological parameter by harmonizing data between two or more different types of non-invasive physiological sensors interrogating the same or proximate measurement sites, the method comprising:

    • receiving a first signal from a first non-invasive sensing device of a first type, wherein the first non-invasive sensing device is configured to interrogate a tissue site of a patient and generate the first signal, wherein the first signal is indicative of first physiological data associated with the tissue site;
    • receiving a second signal from a second non-invasive sensing device of a second type that is different from the first type, wherein the second non-invasive sensing device is configured to interrogate the tissue site of the patient and generate the second signal, wherein the second signal is indicative of second physiological data associated with the tissue site; and/or determining a physiological parameter based at least in part on the first and second signals.


Clause 23: The method of Clause 22, wherein the first non-invasive sensing device comprises one or more of an optical coherence tomography (OCT) sensor, a bioimpedance sensor, or a tissue dielectric constant sensor.


Clause 24: The method of any of Clauses 22 or 23, wherein the first physiological data comprises tissue geometry data corresponding to the tissue site.


Clause 25: The method of any of Clauses 22-24, wherein tissue geometry data comprises at least one of data corresponding to one or more of a thickness of one or more layers of skin of the tissue site, cellular structure information associated with the tissue site, or a water content associated with the tissue site.


Clause 26: The method of Clauses 22-25, wherein the first non-invasive sensing device comprises a plethysmography sensor.


Clause 27: The method of Clauses 22-26, wherein the plethysmography sensor comprises one or more of a pulse oximetry sensor, a transmission plethysmography sensor, or a reflectance plethysmography sensor.


Clause 28: The method of Clauses 22-27, wherein the plethysmography sensor comprises:


at least one emitter configured to emit light, and


at least one detector configured to:

    • detect the light after interaction with the tissue site, and
    • generate the second signal responsive to the detected light.


Clause 29: The method of Clauses 22-28, wherein the first non-invasive sensing device and the second non-invasive sensing device are configured to simultaneously interrogate the tissue site.


Clause 30: The method of Clauses 22-29, wherein the first non-invasive sensing device and the second non-invasive sensing device are configured to interrogate the tissue site at distinct and different time periods.


Clause 31: The method of Clauses 22-30, wherein the second non-invasive sensing device comprises a Raman spectrometer.


Clause 32: The method of Clauses 22-31, wherein the second physiological data corresponds to Raman spectra associated with the tissue site.


Clause 33: The method of Clauses 22-32, further comprising determining an isolated Raman signal by reducing or removing at least one of an effect of fluorescence or an effect of absorption from the second signal.


Clause 34: The method of Clauses 22-33, wherein said determining the isolated Raman signal is based at least in part on the first signal.


Clause 35: The method of Clauses 22-34, further comprising determining a path length associated with the tissue site based at least in part on the first signal, wherein said determining the physiological parameter is based at least in part on the determined path length.


Clause 36: The method of Clauses 22-35, further comprising determining an absorption of light of the tissue site based at least in part on the second signal, wherein said determining the physiological parameter is based at least in part on the determined absorption of light.


Clause 37: The method of Clauses 22-36, wherein physiological parameter comprises a concentration of one or more analytes.


Clause 38: The method of Clauses 22-37, wherein physiological parameter comprises a blood glucose concentration associated with the tissue site.


Clause 39: The method of Clauses 22-38, further comprising calibrating the second non-invasive sensing device based at least in part on the first signal.


Clause 40: The method of Clauses 22-39, wherein second non-invasive sensing device comprises a Raman spectrometer, the method further comprising calibrating the Raman spectrometer by selecting at least one of a focal depth, a focal length, a wavelength, or a refractive index, associated with the Raman spectrometer.


Clause 41: The method of Clauses 22-40, wherein the tissue site comprises a thenar space of a hand.


Clause 42: The method of Clauses 22-41, wherein the tissue site comprises an area associated with a metacarpal bone.


Clause 43: A physiological monitoring device comprising any of the features of any of the previous clauses.


Terminology

The term “and/or” herein has its broadest least limiting meaning which is the disclosure includes A alone, B alone, both A and B together, or A or B alternatively, but does not require both A and B or require one of A or one of B. As used herein, the phrase “at least one of” A, B, “and” C should be construed to mean a logical A or B or C, using a non-exclusive logical or.


The following description is merely illustrative in nature and is in no way intended to limit the disclosure, its application, or uses. For purposes of clarity, the same reference numbers will be used in the drawings to identify similar elements. It should be understood that steps within a method may be executed in different order without altering the principles of the present disclosure.


Features, materials, characteristics, or groups described in conjunction with a particular aspect, embodiment, or example are to be understood to be applicable to any other aspect, embodiment or example described herein unless incompatible therewith. All of the features disclosed in this specification (including any accompanying claims, abstract and drawings), or all of the steps of any method or process so disclosed, may be combined in any combination, except combinations where at least some of such features or steps are mutually exclusive. The protection is not restricted to the details of any foregoing embodiments. The protection extends to any novel one, or any novel combination, of the features disclosed in this specification (including any accompanying claims, abstract and drawings), or to any novel one, or any novel combination, of the steps of any method or process so disclosed.


While certain embodiments have been described, these embodiments have been presented by way of example only, and are not intended to limit the scope of protection. Indeed, the novel methods and systems described herein may be embodied in a variety of other forms. Furthermore, various omissions, substitutions and changes in the form of the methods and systems described herein may be made. Those skilled in the art will appreciate that in some embodiments, the actual steps taken in the processes illustrated or disclosed may differ from those shown in the figures. Depending on the embodiment, certain of the steps described above may be removed, others may be added. For example, the actual steps or order of steps taken in the disclosed processes may differ from those shown in the figures. Depending on the embodiment, certain of the steps described above may be removed, others may be added. For instance, the various components illustrated in the figures may be implemented as software or firmware on a processor, controller, ASIC, FPGA, or dedicated hardware. Hardware components, such as processors, ASICs, FPGAs, and the like, can include logic circuitry. Furthermore, the features and attributes of the specific embodiments disclosed above may be combined in different ways to form additional embodiments, all of which fall within the scope of the present disclosure.


User interface screens illustrated and described herein can include additional or alternative components. These components can include menus, lists, buttons, text boxes, labels, radio buttons, scroll bars, sliders, checkboxes, combo boxes, status bars, dialog boxes, windows, and the like. User interface screens can include additional or alternative information. Components can be arranged, grouped, displayed in any suitable order.


Although the present disclosure includes certain embodiments, examples and applications, it will be understood by those skilled in the art that the present disclosure extends beyond the specifically disclosed embodiments to other alternative embodiments or uses and obvious modifications and equivalents thereof, including embodiments which do not provide all of the features and advantages set forth herein. Accordingly, the scope of the present disclosure is not intended to be limited by the specific disclosures of preferred embodiments herein, and may be defined by claims as presented herein or as presented in the future.


Conditional language, such as “can,” “could,” “might,” or “may,” unless specifically stated otherwise, or otherwise understood within the context as used, is generally intended to convey that certain embodiments include, while other embodiments do not include, certain features, elements, or steps. Thus, such conditional language is not generally intended to imply that features, elements, or steps are in any way required for one or more embodiments or that one or more embodiments necessarily include logic for deciding, with or without user input or prompting, whether these features, elements, or steps are included or are to be performed in any particular embodiment. The terms “comprising,” “including,” “having,” and the like are synonymous and are used inclusively, in an open-ended fashion, and do not exclude additional elements, features, acts, operations, and so forth. Also, the term “or” is used in its inclusive sense (and not in its exclusive sense) so that when used, for example, to connect a list of elements, the term “or” means one, some, or all of the elements in the list. Further, the term “each,” as used herein, in addition to having its ordinary meaning, can mean any subset of a set of elements to which the term “each” is applied.


Conjunctive language such as the phrase “at least one of X, Y, and Z,” unless specifically stated otherwise, is otherwise understood with the context as used in general to convey that an item, term, etc. may be either X, Y, or Z. Thus, such conjunctive language is not generally intended to imply that certain embodiments require the presence of at least one of X, at least one of Y, and at least one of Z.


Language of degree used herein, such as the terms “approximately,” “about,” “generally,” and “substantially” as used herein represent a value, amount, or characteristic close to the stated value, amount, or characteristic that still performs a desired function or achieves a desired result. For example, the terms “approximately”, “about”, “generally,” and “substantially” may refer to an amount that is within less than 10% of, within less than 5% of, within less than 1% of, within less than 0.1% of, and within less than 0.01% of the stated amount. As another example, in certain embodiments, the terms “generally parallel” and “substantially parallel” refer to a value, amount, or characteristic that departs from exactly parallel by less than or equal to 15 degrees, 10 degrees, 5 degrees, 3 degrees, 1 degree, or 0.1 degree.


The scope of the present disclosure is not intended to be limited by the specific disclosures of preferred embodiments in this section or elsewhere in this specification, and may be defined by claims as presented in this section or elsewhere in this specification or as presented in the future. The language of the claims is to be interpreted broadly based on the language employed in the claims and not limited to the examples described in the present specification or during the prosecution of the application, which examples are to be construed as non-exclusive.

Claims
  • 1. A physiological monitoring system configured to determine a physiological parameter by harmonizing data between two or more different types of non-invasive physiological sensors interrogating a shared tissue volume, the physiological monitoring system comprising: a plethysmography sensor configured to generate a first signal indicative of first physiological data associated with a shared tissue volume;a second non-invasive sensing device configured to generate a second signal indicative of tissue geometry data associated with the shared tissue volume, wherein the second non-invasive sensing device comprises at least one of, an optical coherence tomography (OCT) sensor, a tissue dielectric constant sensor, or a bioimpedance sensor; andone or more processors in communication with the plethysmography sensor and the second non-invasive sensing device, the one or more processors configured to: receive the first signal and the second signal,determine a physiological parameter based at least in part on the first signal and the second signal, andoutput a visual or audible indication of the physiological parameter.
  • 2. The system of claim 1, wherein tissue geometry data comprises information related to a thickness of one or more layers of skin of the shared tissue volume, a cellular structure of the shared tissue volume, or a water content of the shared tissue volume.
  • 3. The system of claim 1, wherein the plethysmography sensor and the second non-invasive sensing device concurrently interrogate the shared tissue volume.
  • 4. The system of claim 1, wherein the plethysmography sensor and the second non-invasive sensing device interrogate the shared tissue volume at distinct and different time periods.
  • 5. The system of claim 1, further comprising a Raman spectrometer configured to generate a third signal corresponding to Raman spectra associated with the shared tissue volume.
  • 6. The system of claim 5, wherein the one or more processors are further configured to determine an isolated Raman signal by reducing or removing at least one of an effect of fluorescence or an effect of absorption from the third signal.
  • 7. The system of claim 1, wherein the one or more processors are further configured to determine a path length associated with the shared tissue volume, wherein the physiological parameter is determined based at least in part on the path length associated with the shared tissue volume.
  • 8. The system of claim 1, wherein the one or more processors are further configured to determine an absorption of light of the shared tissue volume, wherein the physiological parameter is determined based at least in part on the absorption of light of the shared tissue volume.
  • 9. The system of claim 1, wherein the physiological parameter comprises a blood glucose concentration associated with the shared tissue volume.
  • 10. The system of claim 1, further comprising a Raman spectrometer, wherein the one or more processors are further configured to calibrate the Raman spectrometer based at least in part on the first signal, wherein to calibrate the Raman spectrometer, the one or more processors are configured to select at least one of a focal depth, a focal length, a wavelength, or a refractive index, associated with the Raman spectrometer.
  • 11. A method for determining a physiological parameter by harmonizing data between two or more different types of non-invasive physiological sensors interrogating a shared tissue volume, the method comprising: receiving a first signal from a plethysmography sensor configured to interrogate a shared tissue volume and generate the first signal, wherein the first signal is indicative of first physiological data associated with the shared tissue volume;receiving a second signal from a bioimpedance sensor, wherein the second signal is indicative of second physiological data associated with the shared tissue volume;determining a physiological parameter based at least in part on the first and second signals; andoutputting a visual or audible indication of the physiological parameter.
  • 12. The method of claim 11, wherein the plethysmography sensor and the bioimpedance sensor concurrently interrogate the shared tissue volume.
  • 13. The method of claim 11, further comprising receiving a third signal from a tissue dielectric constant sensor, wherein the third signal is indicative of third physiological data associated with the shared tissue volume, and wherein said determining the physiological parameter is further based at least in part on the third signal.
  • 14. The method of claim 11, further comprising receiving a third signal from a Raman spectrometer, wherein the third signal is indicative of third physiological data associated with the shared tissue volume, and wherein said determining the physiological parameter is further based at least in part on the third signal.
  • 15. A physiological monitoring system configured to determine a physiological parameter by harmonizing data between two or more different types of non-invasive physiological sensors interrogating a shared volume of tissue, the physiological monitoring system comprising: a plurality of sensors configured to interrogate a shared volume of tissue of a patient, wherein each of the plurality of sensors is configured to generate a sensor signal associated with physiological data of the shared volume of tissue, wherein the plurality of sensors comprises a plethysmography sensor and a bioimpedance sensor; anda processor in communication with each of the plurality of sensors and configured to: receive the plurality of sensor signals,determine a physiological parameter associated with the shared volume of tissue based at least in part on the plurality of sensor signals, andoutput a visual or audible indication of the physiological parameter.
  • 16. The system of claim 13, wherein the plurality of sensors further comprises a temperature sensor, a Raman sensor, an optical coherence tomography (OCT) sensor, and a tissue dielectric constant sensor.
  • 17. The system of claim 13, wherein the plurality of sensors comprises at least four different types of sensors.
  • 18. The system of claim 13, wherein at least two of the plurality of sensors are configured to concurrently interrogate the shared tissue volume.
  • 19. The system of claim 13, wherein each of the plurality of sensors is configured to interrogate the shared tissue volume at a distinct and different time period.
  • 20. A physiological monitoring system configured to determine a physiological parameter by harmonizing data between two or more different types of non-invasive physiological sensors interrogating a shared tissue volume, the physiological monitoring system comprising: a plethysmography sensor configured to generate a first signal indicative of first physiological data associated with a shared tissue volume;a second non-invasive sensing device configured to generate a second signal indicative of second physiological data associated with the shared tissue volume, wherein the second non-invasive sensing device comprises a Raman sensor; andone or more processors in communication with the plethysmography sensor and the second non-invasive sensing device, the one or more processors configured to: receive the first signal and the second signal,determine a physiological parameter based at least in part on the first signal and the second signal, andoutput a visual or audible indication of the physiological parameter.
  • 21. The system of claim 20, wherein the one or more processors are further configured to calibrate the Raman sensor based at least in part on the first signal, wherein to calibrate the Raman sensor, the one or more processors are configured to select at least one of a focal depth, a focal length, a wavelength, or a refractive index associated with the Raman sensor.
  • 22. The system of claim 20, wherein the one or more processors are further configured to determine an isolated Raman signal by reducing or removing at least one of an effect of fluorescence or an effect of absorption from the second signal.
CROSS-REFERENCE TO RELATED APPLICATIONS

The present application claims priority benefit to U.S. Provisional Application No. 62/532,273, entitled “MEDICAL MONITORING DEVICE FOR COORDINATING PHYSIOLOGICAL MEASUREMENTS,” filed Jul. 13, 2017, and U.S. Provisional Application No. 62/667,983, entitled “MEDICAL MONITORING DEVICE FOR HARMONIZING PHYSIOLOGICAL MEASUREMENTS,” filed May 7, 2018, each of which is hereby incorporated herein by reference in its entirety.

US Referenced Citations (981)
Number Name Date Kind
4960128 Gordon et al. Oct 1990 A
4964408 Hink et al. Oct 1990 A
5041187 Hink et al. Aug 1991 A
5069213 Polczynski Dec 1991 A
5163438 Gordon et al. Nov 1992 A
5319355 Russek Jun 1994 A
5337744 Branigan Aug 1994 A
5341805 Stavridi et al. Aug 1994 A
D353195 Savage et al. Dec 1994 S
D353196 Savage et al. Dec 1994 S
5377676 Vari et al. Jan 1995 A
D359546 Savage et al. Jun 1995 S
5431170 Mathews Jul 1995 A
5436499 Namavar et al. Jul 1995 A
D361840 Savage et al. Aug 1995 S
D362063 Savage et al. Sep 1995 S
5452717 Branigan et al. Sep 1995 A
D363120 Savage et al. Oct 1995 S
5456252 Vari et al. Oct 1995 A
5479934 Imran Jan 1996 A
5482036 Diab et al. Jan 1996 A
5490505 Diab et al. Feb 1996 A
5494043 O'Sullivan et al. Feb 1996 A
5533511 Kaspari et al. Jul 1996 A
5534851 Russek Jul 1996 A
5561275 Savage et al. Oct 1996 A
5562002 Lalin Oct 1996 A
5590649 Caro et al. Jan 1997 A
5602924 Durand et al. Feb 1997 A
5632272 Diab et al. May 1997 A
5638816 Kiani-Azarbayjany et al. Jun 1997 A
5638818 Diab et al. Jun 1997 A
5645440 Tobler et al. Jul 1997 A
5671914 Kalkhoran et al. Sep 1997 A
5685299 Diab et al. Nov 1997 A
5726440 Kalkhoran et al. Mar 1998 A
D393830 Tobler et al. Apr 1998 S
5743262 Lepper, Jr. et al. Apr 1998 A
5747806 Khalil et al. May 1998 A
5750994 Schlager May 1998 A
5758644 Diab et al. Jun 1998 A
5760910 Lepper, Jr. et al. Jun 1998 A
5769785 Diab et al. Jun 1998 A
5782757 Diab et al. Jul 1998 A
5785659 Caro et al. Jul 1998 A
5791347 Flaherty et al. Aug 1998 A
5810734 Caro et al. Sep 1998 A
5823950 Diab et al. Oct 1998 A
5830131 Caro et al. Nov 1998 A
5833618 Caro et al. Nov 1998 A
5860919 Kiani-Azarbayjany et al. Jan 1999 A
5890929 Mills et al. Apr 1999 A
5904654 Wohltmann et al. May 1999 A
5919134 Diab Jul 1999 A
5934925 Tobler et al. Aug 1999 A
5940182 Lepper, Jr. et al. Aug 1999 A
5987343 Kinast Nov 1999 A
5995855 Kiani et al. Nov 1999 A
5997343 Mills et al. Dec 1999 A
6002952 Diab et al. Dec 1999 A
6010937 Karam et al. Jan 2000 A
6011986 Diab et al. Jan 2000 A
6027452 Flaherty et al. Feb 2000 A
6036642 Diab et al. Mar 2000 A
6040578 Malin et al. Mar 2000 A
6045509 Caro et al. Apr 2000 A
6066204 Haven May 2000 A
6067462 Diab et al. May 2000 A
6081735 Diab et al. Jun 2000 A
6088607 Diab et al. Jul 2000 A
6110522 Lepper, Jr. et al. Aug 2000 A
6115673 Malin et al. Sep 2000 A
6124597 Shehada Sep 2000 A
6128521 Marro et al. Oct 2000 A
6129675 Jay Oct 2000 A
6144868 Parker Nov 2000 A
6151516 Kiani-Azarbayjany et al. Nov 2000 A
6152754 Gerhardt et al. Nov 2000 A
6157850 Diab et al. Dec 2000 A
6165005 Mills et al. Dec 2000 A
6184521 Coffin, IV et al. Feb 2001 B1
6206830 Diab et al. Mar 2001 B1
6229856 Diab et al. May 2001 B1
6232609 Snyder et al. May 2001 B1
6236872 Diab et al. May 2001 B1
6241683 Macklem et al. Jun 2001 B1
6253097 Aronow et al. Jun 2001 B1
6255708 Sudharsanan et al. Jul 2001 B1
6256523 Diab et al. Jul 2001 B1
6263222 Diab et al. Jul 2001 B1
6278522 Lepper, Jr. et al. Aug 2001 B1
6280213 Tobler et al. Aug 2001 B1
6280381 Malin et al. Aug 2001 B1
6285896 Tobler et al. Sep 2001 B1
6301493 Marro et al. Oct 2001 B1
6308089 von der Ruhr et al. Oct 2001 B1
6317627 Ennen et al. Nov 2001 B1
6321100 Parker Nov 2001 B1
6325761 Jay Dec 2001 B1
6334065 Al-Ali et al. Dec 2001 B1
6343224 Parker Jan 2002 B1
6349228 Kiani et al. Feb 2002 B1
6360114 Diab et al. Mar 2002 B1
6368283 Xu et al. Apr 2002 B1
6371921 Caro et al. Apr 2002 B1
6377829 Al-Ali Apr 2002 B1
6388240 Schulz et al. May 2002 B2
6397091 Diab et al. May 2002 B2
6411373 Garside et al. Jun 2002 B1
6415167 Blank et al. Jul 2002 B1
6430437 Marro Aug 2002 B1
6430525 Weber et al. Aug 2002 B1
6463311 Diab Oct 2002 B1
6470199 Kopotic et al. Oct 2002 B1
6487429 Hockersmith et al. Nov 2002 B2
6501975 Diab et al. Dec 2002 B2
6505059 Kollias et al. Jan 2003 B1
6515273 Al-Ali Feb 2003 B2
6519487 Parker Feb 2003 B1
6525386 Mills et al. Feb 2003 B1
6526300 Kiani et al. Feb 2003 B1
6534012 Hazen et al. Mar 2003 B1
6541756 Schulz et al. Apr 2003 B2
6542764 Al-Ali et al. Apr 2003 B1
6580086 Schulz et al. Jun 2003 B1
6584336 Ali et al. Jun 2003 B1
6587196 Stippick et al. Jul 2003 B1
6587199 Luu Jul 2003 B1
6595316 Cybulski et al. Jul 2003 B2
6597932 Tian et al. Jul 2003 B2
6597933 Kiani et al. Jul 2003 B2
6606511 Ali et al. Aug 2003 B1
6632181 Flaherty et al. Oct 2003 B2
6635559 Greenwald et al. Oct 2003 B2
6639668 Trepagnier Oct 2003 B1
6640116 Diab Oct 2003 B2
6640117 Makarewicz et al. Oct 2003 B2
6643530 Diab et al. Nov 2003 B2
6650917 Diab et al. Nov 2003 B2
6654624 Diab et al. Nov 2003 B2
6658276 Kiani et al. Dec 2003 B2
6661161 Lanzo et al. Dec 2003 B1
6671531 Al-Ali et al. Dec 2003 B2
6678543 Diab et al. Jan 2004 B2
6684090 Ali et al. Jan 2004 B2
6684091 Parker Jan 2004 B2
6697656 Al-Ali Feb 2004 B1
6697657 Shehada et al. Feb 2004 B1
6697658 Al-Ali Feb 2004 B2
RE38476 Diab et al. Mar 2004 E
6699194 Diab et al. Mar 2004 B1
6714804 Al-Ali et al. Mar 2004 B2
RE38492 Diab et al. Apr 2004 E
6721582 Trepagnier et al. Apr 2004 B2
6721585 Parker Apr 2004 B1
6725075 Al-Ali Apr 2004 B2
6728560 Kollias et al. Apr 2004 B2
6735459 Parker May 2004 B2
6738652 Mattu et al. May 2004 B2
6745060 Diab et al. Jun 2004 B2
6760607 Al-Ali Jul 2004 B2
6770028 Ali et al. Aug 2004 B1
6771994 Kiani et al. Aug 2004 B2
6788965 Ruchti et al. Sep 2004 B2
6792300 Diab et al. Sep 2004 B1
6813511 Diab et al. Nov 2004 B2
6816241 Grubisic Nov 2004 B2
6816741 Diab Nov 2004 B2
6822564 Al-Ali Nov 2004 B2
6826419 Diab et al. Nov 2004 B2
6830711 Mills et al. Dec 2004 B2
6850787 Weber et al. Feb 2005 B2
6850788 Al-Ali Feb 2005 B2
6852083 Caro et al. Feb 2005 B2
6861639 Al-Ali Mar 2005 B2
6876931 Lorenz et al. Apr 2005 B2
6898452 Al-Ali et al. May 2005 B2
6920345 Al-Ali et al. Jul 2005 B2
6931268 Kiani-Azarbayjany et al. Aug 2005 B1
6934570 Kiani et al. Aug 2005 B2
6939305 Flaherty et al. Sep 2005 B2
6943348 Coffin, IV Sep 2005 B1
6950687 Al-Ali Sep 2005 B2
6956649 Acosta et al. Oct 2005 B2
6961598 Diab Nov 2005 B2
6970792 Diab Nov 2005 B1
6979812 Al-Ali Dec 2005 B2
6985764 Mason et al. Jan 2006 B2
6990364 Ruchti et al. Jan 2006 B2
6993371 Kiani et al. Jan 2006 B2
6996427 Ali et al. Feb 2006 B2
6998247 Monfre et al. Feb 2006 B2
6999904 Weber et al. Feb 2006 B2
7003338 Weber et al. Feb 2006 B2
7003339 Diab et al. Feb 2006 B2
7015451 Dalke et al. Mar 2006 B2
7024233 Ali et al. Apr 2006 B2
7027849 Al-Ali Apr 2006 B2
7030749 Al-Ali Apr 2006 B2
7039449 Al-Ali May 2006 B2
7041060 Flaherty et al. May 2006 B2
7044918 Diab May 2006 B2
7048687 Reuss et al. May 2006 B1
7067893 Mills et al. Jun 2006 B2
D526719 Richie, Jr. et al. Aug 2006 S
7096052 Mason et al. Aug 2006 B2
7096054 Abdul-Hafiz et al. Aug 2006 B2
D529616 Deros et al. Oct 2006 S
7132641 Schulz et al. Nov 2006 B2
7133710 Acosta et al. Nov 2006 B2
7142901 Kiani et al. Nov 2006 B2
7149561 Diab Dec 2006 B2
7186966 Al-Ali Mar 2007 B2
7190261 Al-Ali Mar 2007 B2
7215984 Diab May 2007 B2
7215986 Diab May 2007 B2
7221971 Diab May 2007 B2
7225006 Al-Ali et al. May 2007 B2
7225007 Al-Ali May 2007 B2
RE39672 Shehada et al. Jun 2007 E
7239905 Kiani-Azarbayjany et al. Jul 2007 B2
7245953 Parker Jul 2007 B1
7254429 Schurman et al. Aug 2007 B2
7254431 Al-Ali Aug 2007 B2
7254433 Diab et al. Aug 2007 B2
7254434 Schulz et al. Aug 2007 B2
7272425 Al-Ali Sep 2007 B2
7274955 Kiani et al. Sep 2007 B2
D554263 Al-Ali Oct 2007 S
7280858 Al-Ali et al. Oct 2007 B2
7289835 Mansfield et al. Oct 2007 B2
7292883 De Felice et al. Nov 2007 B2
7295866 Al-Ali Nov 2007 B2
7328053 Diab et al. Feb 2008 B1
7332784 Mills et al. Feb 2008 B2
7340287 Mason et al. Mar 2008 B2
7341559 Schulz et al. Mar 2008 B2
7343186 Lamego et al. Mar 2008 B2
D566282 Al-Ali et al. Apr 2008 S
7355512 Al-Ali Apr 2008 B1
7356365 Schurman Apr 2008 B2
7371981 Abdul-Hafiz May 2008 B2
7373193 Al-Ali et al. May 2008 B2
7373194 Weber et al. May 2008 B2
7376453 Diab et al. May 2008 B1
7377794 Al Ali et al. May 2008 B2
7377899 Weber et al. May 2008 B2
7383070 Diab et al. Jun 2008 B2
7395158 Monfre et al. Jul 2008 B2
7415297 Al-Ali et al. Aug 2008 B2
7428432 Ali et al. Sep 2008 B2
7438683 Al-Ali et al. Oct 2008 B2
7440787 Diab Oct 2008 B2
7454240 Diab et al. Nov 2008 B2
7467002 Weber et al. Dec 2008 B2
7469157 Diab et al. Dec 2008 B2
7471969 Diab et al. Dec 2008 B2
7471971 Diab et al. Dec 2008 B2
7483729 Al-Ali et al. Jan 2009 B2
7483730 Diab et al. Jan 2009 B2
7489958 Diab et al. Feb 2009 B2
7496391 Diab et al. Feb 2009 B2
7496393 Diab et al. Feb 2009 B2
D587657 Al-Ali et al. Mar 2009 S
7499741 Diab et al. Mar 2009 B2
7499835 Weber et al. Mar 2009 B2
7500950 Al-Ali et al. Mar 2009 B2
7509154 Diab et al. Mar 2009 B2
7509494 Al-Ali Mar 2009 B2
7510849 Schurman et al. Mar 2009 B2
7514725 Wojtczuk et al. Apr 2009 B2
7519406 Blank et al. Apr 2009 B2
7526328 Diab et al. Apr 2009 B2
D592507 Wachman et al. May 2009 S
7530942 Diab May 2009 B1
7530949 Al Ali et al. May 2009 B2
7530955 Diab et al. May 2009 B2
7563110 Al-Ali et al. Jul 2009 B2
7593230 Abul-Haj et al. Sep 2009 B2
7596398 Al-Ali et al. Sep 2009 B2
7606608 Blank et al. Oct 2009 B2
7618375 Flaherty Nov 2009 B2
7620674 Ruchti et al. Nov 2009 B2
D606659 Kiani et al. Dec 2009 S
7629039 Eckerbom et al. Dec 2009 B2
7640140 Ruchti et al. Dec 2009 B2
7647083 Al-Ali et al. Jan 2010 B2
D609193 Al-Ali et al. Feb 2010 S
D614305 Al-Ali et al. Apr 2010 S
7697966 Monfre et al. Apr 2010 B2
7698105 Ruchti et al. Apr 2010 B2
RE41317 Parker May 2010 E
RE41333 Blank et al. May 2010 E
7729733 Al-Ali et al. Jun 2010 B2
7734320 Al-Ali Jun 2010 B2
7761127 Al-Ali et al. Jul 2010 B2
7761128 Al-Ali et al. Jul 2010 B2
7764982 Dalke et al. Jul 2010 B2
D621516 Kiani et al. Aug 2010 S
7791155 Diab Sep 2010 B2
7801581 Diab Sep 2010 B2
7822452 Schurman et al. Oct 2010 B2
RE41912 Parker Nov 2010 E
7844313 Kiani et al. Nov 2010 B2
7844314 Al-Ali Nov 2010 B2
7844315 Al-Ali Nov 2010 B2
7865222 Weber et al. Jan 2011 B2
7873497 Weber et al. Jan 2011 B2
7880606 Al-Ali Feb 2011 B2
7880626 Al-Ali et al. Feb 2011 B2
7891355 Al-Ali et al. Feb 2011 B2
7894868 Al-Ali et al. Feb 2011 B2
7899507 Al-Ali et al. Mar 2011 B2
7899518 Trepagnier et al. Mar 2011 B2
7904132 Weber et al. Mar 2011 B2
7909772 Popov et al. Mar 2011 B2
7910875 Al-Ali Mar 2011 B2
7919713 Al-Ali et al. Apr 2011 B2
7937128 Al-Ali May 2011 B2
7937129 Mason et al. May 2011 B2
7937130 Diab et al. May 2011 B2
7941199 Kiani May 2011 B2
7951086 Flaherty et al. May 2011 B2
7957780 Lamego et al. Jun 2011 B2
7962188 Kiani et al. Jun 2011 B2
7962190 Diab et al. Jun 2011 B1
7976472 Kiani Jul 2011 B2
7988637 Diab Aug 2011 B2
7990382 Kiani Aug 2011 B2
7991446 Al-Ali et al. Aug 2011 B2
8000761 Al-Ali Aug 2011 B2
8008088 Bellott et al. Aug 2011 B2
RE42753 Kiani-Azarbayjany et al. Sep 2011 E
8019400 Diab et al. Sep 2011 B2
8028701 Al-Ali et al. Oct 2011 B2
8029765 Bellott et al. Oct 2011 B2
8036727 Schurman et al. Oct 2011 B2
8036728 Diab et al. Oct 2011 B2
8046040 Ali et al. Oct 2011 B2
8046041 Diab et al. Oct 2011 B2
8046042 Diab et al. Oct 2011 B2
8048040 Kiani Nov 2011 B2
8050728 Al-Ali et al. Nov 2011 B2
RE43169 Parker Feb 2012 E
8118620 Al-Ali et al. Feb 2012 B2
8126528 Diab et al. Feb 2012 B2
8128572 Diab et al. Mar 2012 B2
8130105 Al-Ali et al. Mar 2012 B2
8145287 Diab et al. Mar 2012 B2
8150487 Diab et al. Apr 2012 B2
8175672 Parker May 2012 B2
8180420 Diab et al. May 2012 B2
8182443 Kiani May 2012 B1
8185180 Diab et al. May 2012 B2
8190223 Al-Ali et al. May 2012 B2
8190227 Diab et al. May 2012 B2
8203438 Kiani et al. Jun 2012 B2
8203704 Merritt et al. Jun 2012 B2
8204566 Schurman et al. Jun 2012 B2
8219172 Schurman et al. Jul 2012 B2
8224411 Al-Ali et al. Jul 2012 B2
8228181 Al-Ali Jul 2012 B2
8229532 Davis Jul 2012 B2
8229533 Diab et al. Jul 2012 B2
8233955 Al-Ali et al. Jul 2012 B2
8244325 Al-Ali et al. Aug 2012 B2
8255026 Al-Ali Aug 2012 B1
8255027 Al-Ali et al. Aug 2012 B2
8255028 Al-Ali et al. Aug 2012 B2
8260577 Weber et al. Sep 2012 B2
8265723 McHale et al. Sep 2012 B1
8274360 Sampath et al. Sep 2012 B2
8280473 Al-Ali Oct 2012 B2
8301217 Al-Ali et al. Oct 2012 B2
8306596 Schurman et al. Nov 2012 B2
8310336 Muhsin et al. Nov 2012 B2
8315683 Al-Ali et al. Nov 2012 B2
RE43860 Parker Dec 2012 E
8337403 Al-Ali et al. Dec 2012 B2
8346330 Lamego Jan 2013 B2
8353842 Al-Ali et al. Jan 2013 B2
8355766 MacNeish, III et al. Jan 2013 B2
8359080 Diab et al. Jan 2013 B2
8364223 Al-Ali et al. Jan 2013 B2
8364226 Diab et al. Jan 2013 B2
8374665 Lamego Feb 2013 B2
8385995 Al-ali et al. Feb 2013 B2
8385996 Smith et al. Feb 2013 B2
8388353 Kiani et al. Mar 2013 B2
8399822 Al-Ali Mar 2013 B2
8401602 Kiani Mar 2013 B2
8405608 Al-Ali et al. Mar 2013 B2
8414499 Al-Ali et al. Apr 2013 B2
8418524 Al-Ali Apr 2013 B2
8423106 Lamego et al. Apr 2013 B2
8428967 Olsen et al. Apr 2013 B2
8430817 Al-Ali et al. Apr 2013 B1
8437825 Dalvi et al. May 2013 B2
8455290 Siskavich Jun 2013 B2
8457703 Al-Ali Jun 2013 B2
8457707 Kiani Jun 2013 B2
8463349 Diab et al. Jun 2013 B2
8466286 Bellot et al. Jun 2013 B2
8471713 Poeze et al. Jun 2013 B2
8473020 Kiani et al. Jun 2013 B2
8483787 Al-Ali et al. Jul 2013 B2
8489364 Weber et al. Jul 2013 B2
8498684 Weber et al. Jul 2013 B2
8504128 Blank et al. Aug 2013 B2
8509867 Workman et al. Aug 2013 B2
8515509 Bruinsma et al. Aug 2013 B2
8523781 Al-Ali Sep 2013 B2
8529301 Al-Ali et al. Sep 2013 B2
8532727 Ali et al. Sep 2013 B2
8532728 Diab et al. Sep 2013 B2
D692145 Al-Ali et al. Oct 2013 S
8547209 Kiani et al. Oct 2013 B2
8548548 Al-Ali Oct 2013 B2
8548549 Schurman et al. Oct 2013 B2
8548550 Al-Ali et al. Oct 2013 B2
8560032 Al-Ali et al. Oct 2013 B2
8560034 Diab et al. Oct 2013 B1
8570167 Al-Ali Oct 2013 B2
8570503 Vo et al. Oct 2013 B2
8571617 Reichgott et al. Oct 2013 B2
8571618 Lamego et al. Oct 2013 B1
8571619 Al-Ali et al. Oct 2013 B2
8577431 Lamego et al. Nov 2013 B2
8581732 Al-Ali et al. Nov 2013 B2
8584345 Al-Ali et al. Nov 2013 B2
8588880 Abdul-Hafiz et al. Nov 2013 B2
8600467 Al-Ali et al. Dec 2013 B2
8606342 Diab Dec 2013 B2
8626255 Al-Ali et al. Jan 2014 B2
8630691 Lamego et al. Jan 2014 B2
8634889 Al-Ali et al. Jan 2014 B2
8641631 Sierra et al. Feb 2014 B2
8652060 Al-Ali Feb 2014 B2
8663107 Kiani Mar 2014 B2
8666468 Al-Ali Mar 2014 B1
8667967 Al- Ali et al. Mar 2014 B2
8670811 O'Reilly Mar 2014 B2
8670814 Diab et al. Mar 2014 B2
8676286 Weber et al. Mar 2014 B2
8682407 Al-Ali Mar 2014 B2
RE44823 Parker Apr 2014 E
RE44875 Kiani et al. Apr 2014 E
8688183 Bruinsma et al. Apr 2014 B2
8690799 Telfort et al. Apr 2014 B2
8700112 Kiani Apr 2014 B2
8702627 Telfort et al. Apr 2014 B2
8706179 Parker Apr 2014 B2
8712494 MacNeish, III et al. Apr 2014 B1
8715206 Telfort et al. May 2014 B2
8718735 Lamego et al. May 2014 B2
8718737 Diab et al. May 2014 B2
8718738 Blank et al. May 2014 B2
8720249 Al-Ali May 2014 B2
8721541 Al-Ali et al. May 2014 B2
8721542 Al-Ali et al. May 2014 B2
8723677 Kiani May 2014 B1
8740792 Kiani et al. Jun 2014 B1
8754776 Poeze et al. Jun 2014 B2
8755535 Telfort et al. Jun 2014 B2
8755856 Diab et al. Jun 2014 B2
8755872 Marinow Jun 2014 B1
8761850 Lamego Jun 2014 B2
8764671 Kiani Jul 2014 B2
8768423 Shakespeare et al. Jul 2014 B2
8771204 Telfort et al. Jul 2014 B2
8777634 Kiani et al. Jul 2014 B2
8781543 Diab et al. Jul 2014 B2
8781544 Al-Ali et al. Jul 2014 B2
8781549 Al-Ali et al. Jul 2014 B2
8788003 Schurman et al. Jul 2014 B2
8790268 Al-Ali Jul 2014 B2
8801613 Al-Ali et al. Aug 2014 B2
8821397 Al-Ali et al. Sep 2014 B2
8821415 Al-Ali et al. Sep 2014 B2
8830449 Lamego et al. Sep 2014 B1
8831700 Schurman et al. Sep 2014 B2
8840549 Al-Ali et al. Sep 2014 B2
8847740 Kiani et al. Sep 2014 B2
8849365 Smith et al. Sep 2014 B2
8852094 Al-Ali et al. Oct 2014 B2
8852994 Wojtczuk et al. Oct 2014 B2
8868147 Stippick et al. Oct 2014 B2
8868150 Al-Ali et al. Oct 2014 B2
8870792 Al-Ali et al. Oct 2014 B2
8886271 Kiani et al. Nov 2014 B2
8888539 Al-Ali et al. Nov 2014 B2
8888708 Diab et al. Nov 2014 B2
8892180 Weber et al. Nov 2014 B2
8897847 Al-Ali Nov 2014 B2
8909310 Lamego et al. Dec 2014 B2
8911377 Al-Ali Dec 2014 B2
8912909 Al-Ali et al. Dec 2014 B2
8920317 Al-Ali et al. Dec 2014 B2
8921699 Al-Ali et al. Dec 2014 B2
8922382 Al-Ali et al. Dec 2014 B2
8929964 Al-Ali et al. Jan 2015 B2
8942777 Diab et al. Jan 2015 B2
8948834 Diab et al. Feb 2015 B2
8948835 Diab Feb 2015 B2
8965471 Lamego Feb 2015 B2
8983564 Al-Ali Mar 2015 B2
8989831 Al-Ali et al. Mar 2015 B2
8996085 Kiani et al. Mar 2015 B2
8998809 Kiani Apr 2015 B2
9028429 Telfort et al. May 2015 B2
9037207 Al-Ali et al. May 2015 B2
9060721 Reichgott et al. Jun 2015 B2
9066666 Kiani Jun 2015 B2
9066680 Al-Ali et al. Jun 2015 B1
9072474 Al-Ali et al. Jul 2015 B2
9078560 Schurman et al. Jul 2015 B2
9084569 Weber et al. Jul 2015 B2
9095316 Welch et al. Aug 2015 B2
9106038 Telfort et al. Aug 2015 B2
9107625 Telfort et al. Aug 2015 B2
9107626 Al-Ali et al. Aug 2015 B2
9113831 Al-Ali Aug 2015 B2
9113832 Al-Ali Aug 2015 B2
9119595 Lamego Sep 2015 B2
9131881 Diab et al. Sep 2015 B2
9131882 Al-Ali et al. Sep 2015 B2
9131883 Al-Ali Sep 2015 B2
9131917 Telfort et al. Sep 2015 B2
9138180 Coverston et al. Sep 2015 B1
9138182 Al-Ali et al. Sep 2015 B2
9138192 Weber et al. Sep 2015 B2
9142117 Muhsin et al. Sep 2015 B2
9153112 Kiani et al. Oct 2015 B1
9153121 Kiani et al. Oct 2015 B2
9161696 Al-Ali et al. Oct 2015 B2
9161713 Al-Ali et al. Oct 2015 B2
9167995 Lamego et al. Oct 2015 B2
9176141 Al-Ali et al. Nov 2015 B2
9186102 Bruinsma et al. Nov 2015 B2
9192312 Al-Ali Nov 2015 B2
9192329 Al-Ali Nov 2015 B2
9192351 Telfort et al. Nov 2015 B1
9195385 Al-Ali et al. Nov 2015 B2
9211072 Kiani Dec 2015 B2
9211095 Al-Ali Dec 2015 B1
9218454 Kiani et al. Dec 2015 B2
9226696 Kiani Jan 2016 B2
9241662 Al-Ali et al. Jan 2016 B2
9245668 Vo et al. Jan 2016 B1
9259185 Abdul-Hafiz et al. Feb 2016 B2
9267572 Barker et al. Feb 2016 B2
9277880 Poeze et al. Mar 2016 B2
9289167 Diab et al. Mar 2016 B2
9295421 Kiani et al. Mar 2016 B2
9307928 Al-Ali et al. Apr 2016 B1
9323894 Kiani Apr 2016 B2
D755392 Hwang et al. May 2016 S
9326712 Kiani May 2016 B1
9333316 Kiani May 2016 B2
9339220 Lamego et al. May 2016 B2
9341565 Lamego et al. May 2016 B2
9351673 Diab et al. May 2016 B2
9351675 Al-Ali et al. May 2016 B2
9364181 Kiani et al. Jun 2016 B2
9368671 Wojtczuk et al. Jun 2016 B2
9370325 Al-Ali et al. Jun 2016 B2
9370326 McHale et al. Jun 2016 B2
9370335 Al-ali et al. Jun 2016 B2
9375185 Ali et al. Jun 2016 B2
9386953 Al-Ali Jul 2016 B2
9386961 Al-Ali et al. Jul 2016 B2
9392945 Al-Ali et al. Jul 2016 B2
9397448 Al-Ali et al. Jul 2016 B2
9408542 Kinast et al. Aug 2016 B1
9436645 Al-Ali et al. Sep 2016 B2
9445759 Lamego et al. Sep 2016 B1
9466919 Kiani et al. Oct 2016 B2
9474474 Lamego et al. Oct 2016 B2
9480422 Al-Ali Nov 2016 B2
9480435 Olsen Nov 2016 B2
9492110 Al-Ali et al. Nov 2016 B2
9510779 Poeze et al. Dec 2016 B2
9517024 Kiani et al. Dec 2016 B2
9532722 Lamego et al. Jan 2017 B2
9538949 Al-Ali et al. Jan 2017 B2
9538980 Telfort et al. Jan 2017 B2
9549696 Lamego et al. Jan 2017 B2
9554737 Schurman et al. Jan 2017 B2
9560996 Kiani Feb 2017 B2
9560998 Al-Ali et al. Feb 2017 B2
9566019 Al-Ali et al. Feb 2017 B2
9579039 Jansen et al. Feb 2017 B2
9591975 Dalvi et al. Mar 2017 B2
9622692 Lamego et al. Apr 2017 B2
9622693 Diab Apr 2017 B2
D788312 Al-Ali et al. May 2017 S
9636055 Al-Ali et al. May 2017 B2
9636056 Al-Ali May 2017 B2
9649054 Lamego et al. May 2017 B2
9662052 Al-Ali et al. May 2017 B2
9668679 Schurman et al. Jun 2017 B2
9668680 Bruinsma et al. Jun 2017 B2
9668703 Al-Ali Jun 2017 B2
9675286 Diab Jun 2017 B2
9687160 Kiani Jun 2017 B2
9693719 Al-Ali et al. Jul 2017 B2
9693737 Al-Ali Jul 2017 B2
9697928 Al-Ali et al. Jul 2017 B2
9717425 Kiani et al. Aug 2017 B2
9717458 Lamego et al. Aug 2017 B2
9724016 Al-Ali et al. Aug 2017 B1
9724024 Al-Ali Aug 2017 B2
9724025 Kiani et al. Aug 2017 B1
9730640 Diab et al. Aug 2017 B2
9743887 Al-Ali et al. Aug 2017 B2
9749232 Sampath et al. Aug 2017 B2
9750442 Olsen Sep 2017 B2
9750443 Smith et al. Sep 2017 B2
9750461 Telfort Sep 2017 B1
9759714 Bordelon et al. Sep 2017 B2
9775545 Al-Ali et al. Oct 2017 B2
9775546 Diab et al. Oct 2017 B2
9775570 Al-Ali Oct 2017 B2
9778079 Al-Ali et al. Oct 2017 B1
9782077 Lamego et al. Oct 2017 B2
9782110 Kiani Oct 2017 B2
9787568 Lamego et al. Oct 2017 B2
9788735 Al-Ali Oct 2017 B2
9788768 Al-Ali et al. Oct 2017 B2
9795300 Al-Ali Oct 2017 B2
9795310 Al-Ali Oct 2017 B2
9795358 Telfort et al. Oct 2017 B2
9795739 Al-Ali et al. Oct 2017 B2
9801556 Kiani Oct 2017 B2
9801588 Weber et al. Oct 2017 B2
9808188 Perea et al. Nov 2017 B1
9814418 Weber et al. Nov 2017 B2
9820691 Kiani Nov 2017 B2
9833152 Kiani et al. Dec 2017 B2
9833180 Shakespeare et al. Dec 2017 B2
9839379 Al-Ali et al. Dec 2017 B2
9839381 Weber et al. Dec 2017 B1
9847002 Kiani et al. Dec 2017 B2
9847749 Kiani et al. Dec 2017 B2
9848800 Lee et al. Dec 2017 B1
9848806 Al-Ali et al. Dec 2017 B2
9848807 Lamego Dec 2017 B2
9861298 Eckerbom et al. Jan 2018 B2
9861304 Al-Ali et al. Jan 2018 B2
9861305 Weber et al. Jan 2018 B1
9867578 Al-Ali et al. Jan 2018 B2
9872623 Al-Ali Jan 2018 B2
9876320 Coverston et al. Jan 2018 B2
9877650 Muhsin et al. Jan 2018 B2
9877686 Al-Ali et al. Jan 2018 B2
9891079 Dalvi Feb 2018 B2
9895107 Al-Ali et al. Feb 2018 B2
9924893 Schurman et al. Mar 2018 B2
9924897 Abdul-Hafiz Mar 2018 B1
9936917 Poeze et al. Apr 2018 B2
9955937 Telfort May 2018 B2
9965946 Al-Ali et al. May 2018 B2
D820865 Muhsin et al. Jun 2018 S
9986952 Dalvi et al. Jun 2018 B2
D822215 Al-Ali et al. Jul 2018 S
D822216 Barker et al. Jul 2018 S
10010276 Al-Ali et al. Jul 2018 B2
10086138 Novak, Jr. Oct 2018 B1
10111591 Dyell et al. Oct 2018 B2
D833624 DeJong et al. Nov 2018 S
10123729 Dyell et al. Nov 2018 B2
D835282 Barker et al. Dec 2018 S
D835283 Barker et al. Dec 2018 S
D835284 Barker et al. Dec 2018 S
D835285 Barker et al. Dec 2018 S
10149616 Al-Ali et al. Dec 2018 B2
10154815 Al-Ali et al. Dec 2018 B2
10159412 Lamego et al. Dec 2018 B2
10188348 Al-Ali et al. Jan 2019 B2
RE47218 Al-Ali Feb 2019 E
RE47244 Kiani et al. Feb 2019 E
RE47249 Kiani et al. Feb 2019 E
10205291 Scruggs et al. Feb 2019 B2
10226187 Al-Ali et al. Mar 2019 B2
10231657 Al-Ali et al. Mar 2019 B2
10231670 Blank et al. Mar 2019 B2
RE47353 Kiani et al. Apr 2019 E
10279247 Kiani May 2019 B2
10292664 Al-Ali May 2019 B2
10299720 Brown et al. May 2019 B2
10327337 Schmidt et al. Jun 2019 B2
10327713 Barker et al. Jun 2019 B2
10332630 Al-Ali Jun 2019 B2
10383520 Wojtczuk et al. Aug 2019 B2
10383527 Al-Ali Aug 2019 B2
10388120 Muhsin et al. Aug 2019 B2
D864120 Forrest et al. Oct 2019 S
10441181 Telfort et al. Oct 2019 B1
10441196 Eckerbom et al. Oct 2019 B2
10448844 Al-Ali et al. Oct 2019 B2
10448871 Al-Ali et al. Oct 2019 B2
10456038 Lamego et al. Oct 2019 B2
10463340 Telfort et al. Nov 2019 B2
10471159 Lapotko et al. Nov 2019 B1
10505311 Al-Ali et al. Dec 2019 B2
10524738 Olsen Jan 2020 B2
10532174 Al-Ali Jan 2020 B2
10537285 Shreim et al. Jan 2020 B2
10542903 Al-Ali et al. Jan 2020 B2
10555678 Dalvi et al. Feb 2020 B2
10568553 O'Neil et al. Feb 2020 B2
RE47882 Al-Ali Mar 2020 E
10608817 Haider et al. Mar 2020 B2
D880477 Forrest et al. Apr 2020 S
10617302 Al-Ali et al. Apr 2020 B2
10617335 Al-Ali et al. Apr 2020 B2
10637181 Al-Ali et al. Apr 2020 B2
D887548 Abdul-Hafiz et al. Jun 2020 S
D887549 Abdul-Hafiz et al. Jun 2020 S
10667764 Ahmed et al. Jun 2020 B2
D890708 Forrest et al. Jul 2020 S
10721785 Al-Ali Jul 2020 B2
10736518 Al-Ali et al. Aug 2020 B2
10750984 Pauley et al. Aug 2020 B2
D897098 Al-Ali Sep 2020 S
10779098 Iswanto et al. Sep 2020 B2
10827961 Iyengar et al. Nov 2020 B1
10828007 Telfort et al. Nov 2020 B1
10832818 Muhsin et al. Nov 2020 B2
10849554 Shreim et al. Dec 2020 B2
10856750 Indorf et al. Dec 2020 B2
20010034477 Mansfield et al. Oct 2001 A1
20010039483 Brand et al. Nov 2001 A1
20020010401 Bushmakin et al. Jan 2002 A1
20020058864 Mansfield et al. May 2002 A1
20020133080 Apruzzese et al. Sep 2002 A1
20030013975 Kiani Jan 2003 A1
20030018243 Gerhardt et al. Jan 2003 A1
20030144582 Cohen et al. Jul 2003 A1
20030156288 Barnum et al. Aug 2003 A1
20030212312 Coffin, IV et al. Nov 2003 A1
20040106163 Workman, Jr. et al. Jun 2004 A1
20050055276 Kiani et al. Mar 2005 A1
20050234317 Kiani Oct 2005 A1
20060073719 Kiani Apr 2006 A1
20060161054 Reuss et al. Jul 2006 A1
20060189871 Al-Ali et al. Aug 2006 A1
20060200017 Monfre et al. Sep 2006 A1
20060211926 Yu et al. Sep 2006 A1
20070073116 Kiani et al. Mar 2007 A1
20070180140 Welch et al. Aug 2007 A1
20070244377 Cozad et al. Oct 2007 A1
20070282478 Al-Ali et al. Dec 2007 A1
20080064965 Jay et al. Mar 2008 A1
20080094228 Welch et al. Apr 2008 A1
20080221418 Al-Ali et al. Sep 2008 A1
20090036759 Ault et al. Feb 2009 A1
20090093687 Telfort et al. Apr 2009 A1
20090095926 MacNeish, III Apr 2009 A1
20090247984 Lamego et al. Oct 2009 A1
20090275813 Davis Nov 2009 A1
20090275844 Al-Ali Nov 2009 A1
20100004518 Vo et al. Jan 2010 A1
20100030040 Poeze et al. Feb 2010 A1
20100099964 O'Reilly et al. Apr 2010 A1
20100234718 Sampath et al. Sep 2010 A1
20100270257 Wachman et al. Oct 2010 A1
20110028806 Merritt et al. Feb 2011 A1
20110028809 Goodman Feb 2011 A1
20110040197 Welch et al. Feb 2011 A1
20110082711 Poeze et al. Apr 2011 A1
20110087081 Kiani et al. Apr 2011 A1
20110105854 Kiani et al. May 2011 A1
20110118561 Tari et al. May 2011 A1
20110125060 Telfort et al. May 2011 A1
20110137297 Kiani et al. Jun 2011 A1
20110172498 Olsen et al. Jul 2011 A1
20110208015 Welch et al. Aug 2011 A1
20110230733 Al-Ali Sep 2011 A1
20120123231 O'Reilly May 2012 A1
20120165629 Merritt et al. Jun 2012 A1
20120188538 Patil Jul 2012 A1
20120209082 Al-Ali Aug 2012 A1
20120209084 Olsen et al. Aug 2012 A1
20120226117 Lamego et al. Sep 2012 A1
20120283524 Kiani et al. Nov 2012 A1
20120319816 Al-Ali Dec 2012 A1
20130023775 Lamego et al. Jan 2013 A1
20130041591 Lamego Feb 2013 A1
20130060147 Welch et al. Mar 2013 A1
20130090537 Schemmann et al. Apr 2013 A1
20130096405 Garfio Apr 2013 A1
20130096936 Sampath et al. Apr 2013 A1
20130243021 Siskavich Sep 2013 A1
20130253334 Al-Ali et al. Sep 2013 A1
20130296672 O'Neil et al. Nov 2013 A1
20130296713 Al-Ali et al. Nov 2013 A1
20130324808 Al-Ali et al. Dec 2013 A1
20130331660 Al-Ali et al. Dec 2013 A1
20130345921 Al-Ali et al. Dec 2013 A1
20140012100 Al-Ali et al. Jan 2014 A1
20140051953 Lamego et al. Feb 2014 A1
20140081175 Telfort Mar 2014 A1
20140120564 Workman et al. May 2014 A1
20140121482 Merritt et al. May 2014 A1
20140127137 Bellott et al. May 2014 A1
20140135588 Al-Ali et al. May 2014 A1
20140163344 Al-Ali Jun 2014 A1
20140163402 Lamego et al. Jun 2014 A1
20140166076 Kiani et al. Jun 2014 A1
20140171763 Diab Jun 2014 A1
20140180038 Kiani Jun 2014 A1
20140180154 Sierra et al. Jun 2014 A1
20140180160 Brown et al. Jun 2014 A1
20140187973 Brown et al. Jul 2014 A1
20140213864 Abdul-Hafiz et al. Jul 2014 A1
20140266790 Al-Ali et al. Sep 2014 A1
20140275808 Poeze et al. Sep 2014 A1
20140275835 Lamego et al. Sep 2014 A1
20140275871 Lamego et al. Sep 2014 A1
20140275872 Merritt et al. Sep 2014 A1
20140276115 Dalvi et al. Sep 2014 A1
20140288400 Diab et al. Sep 2014 A1
20140316217 Purdon et al. Oct 2014 A1
20140316218 Purdon et al. Oct 2014 A1
20140316228 Blank et al. Oct 2014 A1
20140323825 Al-Ali et al. Oct 2014 A1
20140323897 Brown et al. Oct 2014 A1
20140323898 Purdon et al. Oct 2014 A1
20140330092 Al-Ali et al. Nov 2014 A1
20140330098 Merritt et al. Nov 2014 A1
20140357966 Al-Ali et al. Dec 2014 A1
20150005600 Blank et al. Jan 2015 A1
20150011907 Purdon et al. Jan 2015 A1
20150012231 Poeze et al. Jan 2015 A1
20150032029 Al-Ali et al. Jan 2015 A1
20150038859 Dalvi et al. Feb 2015 A1
20150073241 Lamego Mar 2015 A1
20150080754 Purdon et al. Mar 2015 A1
20150087936 Al-Ali et al. Mar 2015 A1
20150094546 Al-Ali Apr 2015 A1
20150097701 Al-Ali et al. Apr 2015 A1
20150099950 Al-Ali et al. Apr 2015 A1
20150099955 Al-Ali et al. Apr 2015 A1
20150101844 Al-Ali et al. Apr 2015 A1
20150106121 Muhsin et al. Apr 2015 A1
20150112151 Muhsin et al. Apr 2015 A1
20150116076 Al-Ali et al. Apr 2015 A1
20150165312 Kiani Jun 2015 A1
20150196249 Brown et al. Jul 2015 A1
20150216459 Al-Ali et al. Aug 2015 A1
20150238722 Al-Ali Aug 2015 A1
20150245773 Lamego et al. Sep 2015 A1
20150245794 Al-Ali Sep 2015 A1
20150257689 Al-Ali et al. Sep 2015 A1
20150272514 Kiani et al. Oct 2015 A1
20150351697 Weber et al. Dec 2015 A1
20150359429 Al-Ali et al. Dec 2015 A1
20150366507 Blank Dec 2015 A1
20160029932 Al-Ali Feb 2016 A1
20160058347 Reichgott et al. Mar 2016 A1
20160066824 Al-Ali et al. Mar 2016 A1
20160081552 Wojtczuk et al. Mar 2016 A1
20160095543 Telfort et al. Apr 2016 A1
20160095548 Al-Ali et al. Apr 2016 A1
20160103598 Al-Ali et al. Apr 2016 A1
20160143548 Al-Ali May 2016 A1
20160166182 Al-Ali et al. Jun 2016 A1
20160166183 Poeze et al. Jun 2016 A1
20160192869 Kiani et al. Jul 2016 A1
20160196388 Lamego Jul 2016 A1
20160197436 Barker et al. Jul 2016 A1
20160213281 Eckerbom et al. Jul 2016 A1
20160228043 O'Neil et al. Aug 2016 A1
20160233632 Scruggs et al. Aug 2016 A1
20160234944 Schmidt et al. Aug 2016 A1
20160270735 Diab et al. Sep 2016 A1
20160283665 Sampath et al. Sep 2016 A1
20160287090 Al-Ali et al. Oct 2016 A1
20160287786 Kiani Oct 2016 A1
20160296169 McHale et al. Oct 2016 A1
20160310052 Al-Ali et al. Oct 2016 A1
20160314260 Kiani Oct 2016 A1
20160324486 Al-Ali et al. Nov 2016 A1
20160324488 Olsen Nov 2016 A1
20160327984 Al-Ali et al. Nov 2016 A1
20160328528 Al-Ali et al. Nov 2016 A1
20160331332 Al-Ali Nov 2016 A1
20160354015 Zhang et al. Dec 2016 A1
20160367173 Dalvi et al. Dec 2016 A1
20170000394 Al-Ali et al. Jan 2017 A1
20170007134 Al-Ali et al. Jan 2017 A1
20170007198 Al-Ali et al. Jan 2017 A1
20170014083 Diab et al. Jan 2017 A1
20170014084 Al-Ali et al. Jan 2017 A1
20170024748 Haider Jan 2017 A1
20170027456 Kinast et al. Feb 2017 A1
20170042488 Muhsin Feb 2017 A1
20170055851 Al-Ali Mar 2017 A1
20170055882 Al-Ali et al. Mar 2017 A1
20170055887 Al-Ali Mar 2017 A1
20170055896 Al-Ali et al. Mar 2017 A1
20170079594 Telfort et al. Mar 2017 A1
20170086723 Al-Ali et al. Mar 2017 A1
20170100064 Van Dorpe Apr 2017 A1
20170143281 Olsen May 2017 A1
20170147774 Kiani May 2017 A1
20170156620 Al-Ali et al. Jun 2017 A1
20170173632 Al-Ali Jun 2017 A1
20170187146 Kiani et al. Jun 2017 A1
20170188864 Drury Jul 2017 A1
20170188919 Al-Ali et al. Jul 2017 A1
20170196464 Jansen et al. Jul 2017 A1
20170196470 Lamego et al. Jul 2017 A1
20170202490 Al-Ali et al. Jul 2017 A1
20170224262 Al-Ali Aug 2017 A1
20170228516 Sampath et al. Aug 2017 A1
20170245790 Al-Ali et al. Aug 2017 A1
20170251974 Shreim et al. Sep 2017 A1
20170251975 Shreim et al. Sep 2017 A1
20170258403 Abdul-Hafiz et al. Sep 2017 A1
20170311891 Kiani et al. Nov 2017 A1
20170325728 Al-Ali et al. Nov 2017 A1
20170332976 Al-Ali et al. Nov 2017 A1
20170340293 Al-Ali et al. Nov 2017 A1
20170360310 Kiani et al. Dec 2017 A1
20170367632 Al-Ali et al. Dec 2017 A1
20180008146 Al-Ali et al. Jan 2018 A1
20180014752 Al-Ali et al. Jan 2018 A1
20180028124 Al-Ali et al. Feb 2018 A1
20180055385 Al-Ali Mar 2018 A1
20180055390 Kiani et al. Mar 2018 A1
20180055430 Diab et al. Mar 2018 A1
20180064381 Shakespeare et al. Mar 2018 A1
20180069776 Lamego et al. Mar 2018 A1
20180103874 Lee et al. Apr 2018 A1
20180116575 Perea et al. May 2018 A1
20180125368 Lamego et al. May 2018 A1
20180125430 Al-Ali et al. May 2018 A1
20180130325 Kiani et al. May 2018 A1
20180132769 Weber et al. May 2018 A1
20180132770 Lamego May 2018 A1
20180199871 Pauley et al. Jul 2018 A1
20180242926 Muhsin et al. Aug 2018 A1
20180247353 Al-Ali et al. Aug 2018 A1
20180247712 Muhsin et al. Aug 2018 A1
20180256087 Al-Ali et al. Sep 2018 A1
20180296161 Shreim et al. Oct 2018 A1
20180300919 Muhsin et al. Oct 2018 A1
20180310822 Indorf et al. Nov 2018 A1
20180310823 Al-Ali et al. Nov 2018 A1
20180317826 Muhsin et al. Nov 2018 A1
20190015023 Monfre Jan 2019 A1
20190117070 Muhsin et al. Apr 2019 A1
20190200941 Chandran et al. Jul 2019 A1
20190239787 Pauley et al. Aug 2019 A1
20190320906 Olsen Oct 2019 A1
20190374139 Kiani et al. Dec 2019 A1
20190374173 Kiani et al. Dec 2019 A1
20190374713 Kiani et al. Dec 2019 A1
20200021930 Iswanto et al. Jan 2020 A1
20200060869 Telfort et al. Feb 2020 A1
20200111552 Ahmed Apr 2020 A1
20200113435 Muhsin Apr 2020 A1
20200113488 Al-Ali et al. Apr 2020 A1
20200113496 Scruggs et al. Apr 2020 A1
20200113497 Triman et al. Apr 2020 A1
20200113520 Abdul-Hafiz et al. Apr 2020 A1
20200138288 Al-Ali et al. May 2020 A1
20200138368 Kiani et al. May 2020 A1
20200163597 Dalvi et al. May 2020 A1
20200196877 Vo et al. Jun 2020 A1
20200253474 Muhsin et al. Aug 2020 A1
20200253544 Belur Nagaraj et al. Aug 2020 A1
20200275841 Telfort et al. Sep 2020 A1
20200288983 Telfort et al. Sep 2020 A1
20200321793 Al-Ali et al. Oct 2020 A1
20200329983 Al-Ali et al. Oct 2020 A1
20200329984 Al-Ali et al. Oct 2020 A1
20200329993 Al-Ali et al. Oct 2020 A1
20200330037 Al-Ali et al. Oct 2020 A1
Foreign Referenced Citations (2)
Number Date Country
3056141 Aug 2016 EP
3056141 Aug 2016 PL
Non-Patent Literature Citations (1)
Entry
International Search Report and Written Opinion, re PCT Application No. PCT/US2018/042148, dated Nov. 19, 2018.
Related Publications (1)
Number Date Country
20190015023 A1 Jan 2019 US
Provisional Applications (2)
Number Date Country
62532273 Jul 2017 US
62667983 May 2018 US